



US 20190036045A1

(19) **United States**

(12) **Patent Application Publication**  
**HWANG et al.**

(10) **Pub. No.: US 2019/0036045 A1**  
(43) **Pub. Date: Jan. 31, 2019**

(54) **ORGANOMETALLIC COMPOUND,  
ORGANIC LIGHT-EMITTING DEVICE  
INCLUDING THE SAME, AND DIAGNOSTIC  
COMPOSITION INCLUDING THE  
ORGANOMETALLIC COMPOUND**

(52) **U.S. Cl.**  
CPC ..... **H01L 51/0087** (2013.01); **H01L 51/5016**  
(2013.01); **C09K 11/06** (2013.01); **C07F**  
**15/0086** (2013.01)


(71) Applicant: **Samsung Electronics Co., Ltd.,**  
Suwon-si (KR)

(57) **ABSTRACT**

(72) Inventors: **Kyuyoung HWANG**, Anyang-si (KR);  
**Seungyeon KWAK**, Suwon-si (KR);  
**Soyeon KIM**, Seoul (KR); **Sunyoung**  
**LEE**, Seoul (KR); **Jungin LEE**, Seoul  
(KR); **Hyeonho CHOI**, Seoul (KR);  
**Whail CHOI**, Seoul (KR); **Yoonhyun**  
**KWAK**, Seoul (KR); **Byoungki CHOI**,  
Hwaseong-si (KR)

An organometallic compound represented by Formula 1:

Formula 1



wherein, in Formula 1, groups and variables are the same as described in the specification.

(21) Appl. No.: **16/043,323**


(22) Filed: **Jul. 24, 2018**


(30) **Foreign Application Priority Data**

Jul. 26, 2017 (KR) ..... 10-2017-0094963

**Publication Classification**

(51) **Int. Cl.**  
**H01L 51/00** (2006.01)  
**C07F 15/00** (2006.01)  
**C09K 11/06** (2006.01)





**ORGANOMETALLIC COMPOUND,  
ORGANIC LIGHT-EMITTING DEVICE  
INCLUDING THE SAME, AND DIAGNOSTIC  
COMPOSITION INCLUDING THE  
ORGANOMETALLIC COMPOUND**

Formula 1

CROSS-REFERENCE TO RELATED  
APPLICATION

**[0001]** This application claims priority to Korean Patent Application No. 10-2017-0094963, filed on Jul. 26, 2017, in the Korean Intellectual Property Office, and all the benefits accruing therefrom under 35 U.S.C. § 119, the content of which is incorporated herein in its entirety by reference.

BACKGROUND

1. Field

**[0002]** One or more embodiments relate to an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

2. Description of the Related Art

**[0003]** Organic light-emitting devices (OLEDs) are self-emission devices, which have superior characteristics in terms of a viewing angle, a response time, luminance, a driving voltage, and a response speed, and which produce full-color images.

**[0004]** In an example, an organic light-emitting device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. These excitons transit from an excited state to a ground state, thereby generating light.

**[0005]** Meanwhile, luminescent compounds may be used to monitor, sense, or detect a variety of biological materials including cells and proteins. An example of such luminescent compounds is a phosphorescent luminescent compound.


**[0006]** Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.

SUMMARY

**[0007]** Aspects of the present disclosure provide an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

**[0008]** Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

**[0009]** According to one or more embodiments, an organometallic compound represented by Formula 1 is provided.



**[0010]** In Formula 1,

**[0011]** M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au),

**[0012]** X<sub>1</sub> may be a chemical bond, O, S, N(R'), P(R'), B(R'), C(R')(R''), Si(R')(R''), or N(R')(R''), and when X<sub>1</sub> is a chemical bond, Y<sub>1</sub> is directly bonded with M,

**[0013]** a bond between X<sub>1</sub> and M may be a covalent bond,

**[0014]** X<sub>2</sub> to X<sub>4</sub> may each independently be N or C,

**[0015]** one bond selected from a bond between X<sub>2</sub> and M, a bond between X<sub>3</sub> and M, and a bond between X<sub>4</sub> and M is a covalent bond, and the remaining two bonds are coordinate bonds,

**[0016]** Y<sub>1</sub> and Y<sub>3</sub> to Y<sub>5</sub> may each independently be C or N,

**[0017]** regarding a pair of X<sub>2</sub> and Y<sub>3</sub>, a pair of X<sub>2</sub> and Y<sub>4</sub>, a pair of Y<sub>4</sub> and Y<sub>5</sub>, a pair of X<sub>51</sub> and Y<sub>5</sub>, and a pair of X<sub>51</sub> and Y<sub>5</sub>, components constituting each pair may be connected to each other via a chemical bond,

**[0018]** CY<sub>1</sub> to CY<sub>5</sub> may each independently be selected from a C<sub>5</sub>-C<sub>30</sub> carbocyclic group and a C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

**[0019]** a cyclometalated ring formed by CY<sub>5</sub>, CY<sub>2</sub>, CY<sub>3</sub>, and M may be a 6-membered ring,

**[0020]** X<sub>51</sub> may be selected from O, S, N-[(L<sub>7</sub>)<sub>b7</sub>-(R<sub>7</sub>)<sub>c7</sub>], C(R<sub>7</sub>)(R<sub>8</sub>), Si(R<sub>7</sub>)(R<sub>8</sub>), Ge(R<sub>7</sub>)(R<sub>8</sub>), C(=O), N, C(R<sub>7</sub>), Si(R<sub>7</sub>), and Ge(R<sub>7</sub>),

**[0021]** R<sub>7</sub> and R<sub>8</sub> may be optionally bonded to each other via a first linking group to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

**[0022]** L<sub>1</sub> to L<sub>4</sub> and L<sub>7</sub> may each independently be selected from a single bond, a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, and a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

**[0023]** b<sub>1</sub> to b<sub>4</sub> and b<sub>7</sub> may each independently be an integer from 1 to 5,

**[0024]** R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R', and R'' may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF<sub>5</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a

- phosphoric acid group or a salt thereof, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> arylthio group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), and —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>).
- [0025]** c1 to c4 and c7 may each independently be an integer from 1 to 5,
- [0026]** Z<sub>1</sub> to Z<sub>4</sub> may each independently be a cyano group (CN)-containing group,
- [0027]** a1 to a4 and n1, n2, n3, and n4 may each independently be an integer from 0 to 20,
- [0028]** two of a plurality of neighboring groups R<sub>1</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,
- [0029]** two of a plurality of neighboring groups R<sub>2</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,
- [0030]** two of a plurality of neighboring groups R<sub>3</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,
- [0031]** two of a plurality of neighboring groups R<sub>4</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,
- [0032]** two or more neighboring substituents selected from groups R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, and R<sub>8</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,
- [0033]** i) when X<sub>51</sub> is O, S, C(=O), or N, the sum of n1, n2, n3, and n4 may be 1 or more,
- [0034]** ii) when X<sub>51</sub> is N[(L<sub>7</sub>)<sub>b7</sub>-(R<sub>7</sub>)<sub>c7</sub>], C(R<sub>7</sub>), Si(R<sub>7</sub>), or Ge(R<sub>7</sub>), R<sub>7</sub> may be a cyano group-containing group or the sum of n1, n2, n3, and n4 may be 1 or more, iii) when X<sub>51</sub> is C(R<sub>7</sub>)(R<sub>8</sub>), Si(R<sub>7</sub>)(R<sub>8</sub>), or Ge(R<sub>7</sub>)(R<sub>8</sub>), at least one selected from R<sub>7</sub> and R<sub>8</sub> may be a cyano group-containing group or the sum of n1, n2, n3, and n4 may be 1 or more,
- [0035]** at least one of substituents of the substituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, substituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, substituted C<sub>1</sub>-C<sub>60</sub> alkyl group, substituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, substituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, substituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, substituted C<sub>6</sub>-C<sub>60</sub> aryl group, substituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, substituted C<sub>6</sub>-C<sub>60</sub> arylthio group, substituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, substituted monovalent non-aromatic condensed polycyclic group, and substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:
- [0036]** deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, and a C<sub>1</sub>-C<sub>60</sub> alkoxy group;
- [0037]** a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, and a C<sub>1</sub>-C<sub>60</sub> alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>11</sub>)(Q<sub>12</sub>), —Si(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —B(Q<sub>16</sub>)(Q<sub>17</sub>), and —P(=O)(Q<sub>18</sub>)(Q<sub>19</sub>);
- [0038]** a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;
- [0039]** a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>21</sub>)(Q<sub>22</sub>), —Si(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —B(Q<sub>26</sub>)(Q<sub>27</sub>), and —P(=O)(Q<sub>28</sub>)(Q<sub>29</sub>); and
- [0040]** —N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>) and —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>),
- [0041]** wherein Q<sub>1</sub> to Q<sub>9</sub>, Q<sub>11</sub> to Q<sub>19</sub>, Q<sub>21</sub> to Q<sub>29</sub>, and Q<sub>31</sub> to Q<sub>39</sub> may each independently be selected from hydro-

gen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>1</sub>-C<sub>60</sub> alkyl group substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, and a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryl group substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, and a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0042] Another aspect of the present disclosure provides an organic light-emitting device including:

[0043] a first electrode,

[0044] a second electrode, and

[0045] an organic layer disposed between the first electrode and the second electrode,

[0046] wherein the organic layer includes an emission layer and at least one organometallic compound.

[0047] The organometallic compound of the organic layer may act as a dopant.

[0048] Another aspect of the present disclosure provides a diagnostic composition including at least one organometallic compound represented by Formula 1.

#### BRIEF DESCRIPTION OF THE DRAWING

[0049] These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the FIGURE which is a schematic view of an organic light-emitting device according to an embodiment.

#### DETAILED DESCRIPTION

[0050] Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

[0051] It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

[0052] It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

[0053] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0054] The term “or” means “and/or.” It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.


[0055] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this general inventive concept belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0056] Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

[0057] “About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within  $\pm 30\%$ , 20%, 10%, 5% of the stated value.

[0058] In an embodiment, an organometallic compound is provided. The organometallic compound according to an embodiment is represented by Formula 1 below:

Formula 1



**[0059]** M in Formula 1 may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), rhenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au).

**[0060]** For example, M in Formula 1 may be platinum, but embodiments of the present disclosure are not limited thereto.

**[0061]** The organometallic compound represented by Formula 1 may not consist of an ion pair of a cation and an anion, that is, may be neutral.

**[0062]** X<sub>1</sub> in Formula 1 may be a chemical bond (for example, a single bond or a covalent bond), O, S, N(R'), P(R'), B(R'), C(R')(R''), Si(R')(R''), or N(R')(R''), and a bond between X<sub>1</sub> and M may be a covalent bond. When X<sub>1</sub> is a chemical bond, Y<sub>1</sub> may be directly bonded with M.

**[0063]** For example, X<sub>1</sub> in Formula 1 may be chemical bond or O, but embodiments of the present disclosure are not limited thereto.

**[0064]** In Formula 1, X<sub>2</sub> to X<sub>4</sub> may each independently be N or C, and one bond selected from a bond between X<sub>2</sub> and M, a bond between X<sub>3</sub> and M, and a bond between X<sub>4</sub> and M may be a covalent bond, and the remaining two bonds may each be a coordinate bond.

**[0065]** For example, in Formula 1,

**[0066]** i) X<sub>2</sub> and X<sub>4</sub> may each be N, X<sub>3</sub> may be C, a bond between X<sub>2</sub> and M and a bond between X<sub>4</sub> and M may each be a coordinate bond, and a bond between X<sub>3</sub> and M may be a covalent bond,

**[0067]** ii) X<sub>3</sub> and X<sub>4</sub> may each be N, X<sub>2</sub> may be N, a bond between X<sub>3</sub> and M and a bond between X<sub>4</sub> and M may each be a coordinate bond, and a bond between X<sub>2</sub> and M may be a covalent bond,

**[0068]** iii) X<sub>2</sub> and X<sub>3</sub> may each be N, X<sub>4</sub> may be N, a bond between X<sub>2</sub> and M may be a covalent bond, and a bond between X<sub>3</sub> and M and a bond between X<sub>4</sub> and M may each be coordinate bond, or

**[0069]** iv) X<sub>2</sub> and X<sub>3</sub> may each be N, X<sub>4</sub> may be C, a bond between X<sub>2</sub> and M and a bond between X<sub>3</sub> and M may each be a coordinate bond, and a bond between X<sub>4</sub> and M may be a covalent bond, but embodiments of the present disclosure are not limited thereto.

**[0070]** Y<sub>1</sub> and Y<sub>3</sub> to Y<sub>5</sub> in Formula 1 may each independently be C or N.

**[0071]** A pair of X<sub>2</sub> and Y<sub>3</sub>, a pair of X<sub>2</sub> and Y<sub>4</sub>, a pair of Y<sub>4</sub> and Y<sub>5</sub>, a pair of X<sub>51</sub> and Y<sub>3</sub>, and a pair of X<sub>51</sub> and Y<sub>5</sub>

in Formula 1 may each be bonded via a chemical bond (for example, a single bond, a double bond, a bond constituting a carbene ligand, or the like) to form a part of CY<sub>1</sub> to CY<sub>5</sub>.

**[0072]** CY<sub>1</sub> to CY<sub>5</sub> in Formula 1 may each independently be selected from a C<sub>5</sub>-C<sub>30</sub> carbocyclic group and a C<sub>1</sub>-C<sub>30</sub> heterocyclic group.

**[0073]** In one or more embodiments, in Formula 1,

**[0074]** CY<sub>1</sub>, CY<sub>2</sub>, and CY<sub>4</sub> may each independently be a 6-membered ring group,

**[0075]** CY<sub>3</sub> may be selected from a 6-membered ring group, a fluorene group, a carbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, and an azadibenzosilole group,

**[0076]** CY<sub>5</sub> may be a 5-membered ring.

**[0077]** In one or more embodiments, CY<sub>1</sub> to CY<sub>4</sub> in Formula 1 may each independently be selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinoxaline group, phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group, but embodiments of the present disclosure are not limited thereto.

**[0078]** In one or more embodiments, CY<sub>1</sub> to CY<sub>4</sub> in Formula 1 may each independently be selected from a) 6-membered ring, b) a condensed ring in which two or more 6-membered rings are condensed with each other, or c) a condensed ring in which one or more 6-membered ring is condensed with one or more 5-membered ring,

**[0079]** the 6-membered ring may be selected from a cyclohexane group, a cyclohexene group, an adamantane group, a norbornane group, a norbornene group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, and a triazine group, and

**[0080]** the 5-membered ring may be selected from a cyclopentane group, a cyclopentene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group and thiadiazole group.

**[0081]** A cyclometalated ring formed by CY<sub>5</sub>, CY<sub>2</sub>, CY<sub>3</sub>, and M in Formula 1 is a 6-membered ring.

**[0082]** X<sub>51</sub> in Formula 1 may be selected from O, S, N-[(L<sub>7</sub>)<sub>b7</sub>-(R<sub>7</sub>)<sub>c7</sub>], C(R<sub>7</sub>)(R<sub>8</sub>), Si(R<sub>7</sub>)(R<sub>8</sub>), Ge(R<sub>7</sub>)(R<sub>8</sub>), C(=O), N, C(R<sub>7</sub>), Si(R<sub>7</sub>), and Ge(R<sub>7</sub>), and R<sub>7</sub> and R<sub>8</sub> may

optionally be linked via a first linking group to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group (for example, a 5-membered to 7-membered cyclic group having the carbon number of 5 or 6; or a 5-membered to 7-membered cyclic group of which the carbon number is 5 or 6 and which is substituted with at least one selected from deuterium, a cyano group, —F, a C<sub>1</sub>-C<sub>10</sub> alkyl group, and a C<sub>6</sub>-C<sub>14</sub> aryl group). L<sub>7</sub>, b7, R<sub>7</sub>, R<sub>8</sub>, and c7 will be described in detail.

**[0083]** The first linking group may be selected from a single bond, \*—O—\*, \*—S—\*, \*—C(R<sub>5</sub>)(R<sub>6</sub>)—\*, \*—C(R<sub>5</sub>)=\*, \*—C(R<sub>6</sub>)—\*, \*—C(R<sub>5</sub>)=C(R<sub>6</sub>)—\*, \*—C(=O)—\*, \*—C(=S)—\*, \*—C≡C—\*, \*—N(R<sub>5</sub>)—\*, \*—Si(R<sub>5</sub>)(R<sub>6</sub>)—\*, and \*—P(R<sub>5</sub>)(R<sub>6</sub>)—\*, R<sub>5</sub> and R<sub>6</sub> may be the same as described in connection with R<sub>1</sub>, and \* and \*' each indicate a binding site to a neighboring atom.

**[0084]** In one or more embodiments, in Formula 1,

**[0085]** i) Y<sub>3</sub> to Y<sub>5</sub> may each be C, a bond between X<sub>51</sub> and Y<sub>3</sub> and a bond between X<sub>51</sub> and Y<sub>5</sub> may each be a single bond, and X<sub>51</sub> may be O, S, N-[(L<sub>7</sub>)<sub>b7</sub>-(R<sub>7</sub>)<sub>c7</sub>], C(R<sub>7</sub>)(R<sub>8</sub>), Si(R<sub>7</sub>)(R<sub>8</sub>), Ge(R<sub>7</sub>)(R<sub>8</sub>), or C(=O),

**[0086]** ii) Y<sub>3</sub> and Y<sub>4</sub> may each be C, Y<sub>5</sub> may be N, a bond between X<sub>51</sub> and Y<sub>3</sub> may be a double bond, a bond between X<sub>51</sub> and Y<sub>5</sub> may be a single bond, and X<sub>51</sub> may be N, C(R<sub>7</sub>), Si(R<sub>7</sub>), or Ge(R<sub>7</sub>),

**[0087]** iii) Y<sub>3</sub> and Y<sub>5</sub> may each be C, Y<sub>4</sub> may be N, a bond between X<sub>51</sub> and Y<sub>3</sub> may be a single bond, a bond between X<sub>51</sub> and Y<sub>5</sub> may be a double bond, and X<sub>51</sub> may be N, C(R<sub>7</sub>), Si(R<sub>7</sub>), or Ge(R<sub>7</sub>),

**[0088]** iv) Y<sub>3</sub> may be N, Y<sub>4</sub> and Y<sub>5</sub> may each be C, a bond between X<sub>51</sub> and Y<sub>3</sub> may be a single bond, a bond between X<sub>51</sub> and Y<sub>5</sub> may be a double bond, and X<sub>51</sub> may be N, C(R<sub>7</sub>), Si(R<sub>7</sub>), or Ge(R<sub>7</sub>), or

**[0089]** v) Y<sub>3</sub> to Y<sub>5</sub> may each be C, a bond between X<sub>51</sub> and Y<sub>3</sub> may be a double bond, a bond between X<sub>51</sub> and Y<sub>5</sub> may be a single bond, and X<sub>51</sub> may be N, C(R<sub>7</sub>), Si(R<sub>7</sub>), or Ge(R<sub>7</sub>).

**[0090]** L<sub>1</sub> to L<sub>4</sub> and L<sub>7</sub> in Formula 1 may each independently be selected from a single bond, a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, and a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group.

**[0091]** For example, L<sub>1</sub> to L<sub>4</sub> and L<sub>7</sub> in Formula 1 may each independently be selected from:

**[0092]** a single bond, a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, and a benzothiadiazole group; and

**[0093]** a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, and a benzothiadiazole group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>20</sub> alkyl group, a C<sub>1</sub>-C<sub>20</sub> alkoxy group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a fluorenyl group, a dimethylfluorenyl group, a diphenylfluorenyl group, a carbazolyl group, a phenylcarbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a dimethyldibenzosilolyl group, a diphenyldibenzosilolyl group, —N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>), and —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>);

**[0094]** Q<sub>31</sub> to Q<sub>39</sub> may each independently be selected from:

**[0095]** —CH<sub>3</sub>, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CH<sub>2</sub>CH<sub>3</sub>, —CH<sub>2</sub>CD<sub>3</sub>, —CH<sub>2</sub>CD<sub>2</sub>H, —CH<sub>2</sub>CDH<sub>2</sub>, —CHDCH<sub>3</sub>, —CHDCD<sub>2</sub>H, —CHDCDH<sub>2</sub>, —CHDCD<sub>3</sub>, —CD<sub>2</sub>CD<sub>3</sub>, —CD<sub>2</sub>CD<sub>2</sub>H, and —CD<sub>2</sub>CDH<sub>2</sub>;

**[0096]** an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

**[0097]** an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>10</sub> alkyl group, and a phenyl group,

**[0098]** but embodiments of the present disclosure are not limited thereto.

**[0099]** b1 to b4 and b7 in Formula 1 indicate numbers of L<sub>1</sub> to L<sub>4</sub> and L<sub>7</sub>, respectively, and may each independently be an integer from 1 to 5. When b1 is 2 or more, two or more groups L<sub>1</sub> may be identical to or different from each other. b2 to b4 and b7 may each be the same as described in connection with b1.

**[0100]** In an embodiment, b1 to b4 and b7 in Formula 1 may each be 1 or 2, but embodiments of the present disclosure are not limited thereto.

**[0101]** R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R' and R'' in Formula 1 may each independently be selected from hydrogen, deuterium, —F,

—Cl, —Br, —I, —SF<sub>5</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> arylthio group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), and —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>).

[0102] For example, R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R', and R'' may each independently be selected from:

[0103] hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF<sub>5</sub>, C<sub>1</sub>-C<sub>20</sub> alkyl group, and a C<sub>1</sub>-C<sub>20</sub> alkoxy group;

[0104] a C<sub>1</sub>-C<sub>20</sub> alkyl group and a C<sub>1</sub>-C<sub>20</sub> alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>10</sub> alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

[0105] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a tri-

azolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

[0106] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group and —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>); and

[0107]  $-\text{N}(\text{Q}_1)(\text{Q}_2)$ ,  $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$ ,  $-\text{B}(\text{Q}_6)(\text{Q}_7)$  and  $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$ ;

[0108] wherein  $\text{Q}_1$  to  $\text{Q}_9$  and  $\text{Q}_{33}$  to  $\text{Q}_{35}$  are each the same as described in connection with  $\text{Q}_{31}$ .

[0109] In an embodiment, the  $\text{R}_1$  to  $\text{R}_4$ ,  $\text{R}_7$ ,  $\text{R}_8$ ,  $\text{R}'$  and  $\text{R}''$  are each independently selected from:

[0110] hydrogen, deuterium,  $-\text{F}$ , a cyano group, a nitro group,  $-\text{SF}_5$ , a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group;

[0111] a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group, each substituted with at least one selected from deuterium,  $-\text{F}$ ,  $-\text{CD}_3$ ,  $-\text{CD}_2\text{H}$ ,  $-\text{CDH}_2$ ,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{H}$ ,  $-\text{CFH}_2$ , a cyano group, a nitro group, a  $\text{C}_1$ - $\text{C}_{10}$  alkyl group, a  $\text{C}_1$ - $\text{C}_{10}$  alkoxy group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, an adamantanyl group, a norbornenyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group, and  $-\text{Si}(\text{Q}_{33})(\text{Q}_{34})(\text{Q}_{35})$ ; and


[0112]  $-\text{N}(\text{Q}_1)(\text{Q}_2)$ ,  $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$ ,  $-\text{B}(\text{Q}_6)(\text{Q}_7)$  and  $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$ ,

[0113] wherein  $\text{Q}_1$  to  $\text{Q}_9$  and  $\text{Q}_{33}$  to  $\text{Q}_{35}$  may be the same as described above, but embodiments of the present disclosure are not limited thereto.

[0114] In one or more embodiments,  $\text{R}_1$  to  $\text{R}_4$ ,  $\text{R}_7$ ,  $\text{R}_8$ ,  $\text{R}'$ , and  $\text{R}''$  may each independently be selected from hydrogen, deuterium,  $-\text{F}$ , a cyano group, a nitro group,  $-\text{SF}_5$ ,  $-\text{CH}_3$ ,  $-\text{CD}_3$ ,  $-\text{CD}_2\text{H}$ ,  $-\text{CDH}_2$ ,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{H}$ ,  $-\text{CFH}_2$ ,  $-\text{C}(\text{CD}_3)_3$ , groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-140,  $-\text{N}(\text{Q}_1)(\text{Q}_2)$ ,  $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$ ,  $-\text{B}(\text{Q}_6)(\text{Q}_7)$  and  $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$  (wherein  $\text{Q}_1$  to  $\text{Q}_9$  may each be the same as described above), but embodiments of the present disclosure are not limited thereto:



Formula 9-1




Formula 9-2




Formula 9-3




Formula 9-4




Formula 9-5




Formula 9-6




Formula 9-7




Formula 9-8




Formula 9-9



Formula 9-10



Formula 9-11
















Formula 9-12




Formula 9-13


-continued



Formula 9-14




Formula 9-15




Formula 9-16

Formula 9-17




Formula 9-18

Formula 9-19




Formula 10-1


Formula 10-2




Formula 10-3




Formula 10-4




Formula 10-5



Formula 10-6



Formula 10-7



-continued

Formula 10-8

Formula 10-9

Formula 10-10

Formula 10-11

Formula 10-12

Formula 10-13


Formula 10-14

Formula 10-15


Formula 10-16

Formula 10-17


-continued




Formula 10-18




Formula 10-19




Formula 10-20




Formula 10-21




Formula 10-22




Formula 10-23




Formula 10-24



Formula 10-25




Formula 10-26




Formula 10-27


-continued




Formula 10-28




Formula 10-29




Formula 10-30




Formula 10-31




Formula 10-32




Formula 10-33




Formula 10-34



Formula 10-35













Formula 10-36




Formula 10-37

-continued




-continued


Formula 10-38




Formula 10-39




Formula 10-40



Formula 10-41




Formula 10-42




Formula 10-43

Formula 10-44




Formula 10-45

Formula 10-46



Formula 10-47



Formula 10-48

Formula 10-49

Formula 10-50

Formula 10-51


Formula 10-52

Formula 10-53


Formula 10-54

Formula 10-55


-continued




Formula 10-56




Formula 10-57




Formula 10-58




Formula 10-59




Formula 10-60



Formula 10-61




Formula 10-62




Formula 10-63


-continued




Formula 10-64




Formula 10-65




Formula 10-66




Formula 10-67




Formula 10-68




Formula 10-69



Formula 10-70









Formula 10-71




Formula 10-72

-continued




-continued


Formula 10-73




Formula 10-74




Formula 10-75







Formula 10-76



Formula 10-77



Formula 10-78



Formula 10-79

Formula 10-80

Formula 10-81

Formula 10-82













Formula 10-83

Formula 10-84


Formula 10-85

Formula 10-86


-continued




Formula 10-87




Formula 10-88




Formula 10-89




Formula 10-90




Formula 10-91




Formula 10-92




Formula 10-93




Formula 10-94



Formula 10-95



Formula 10-96



Formula 10-98

Formula 10-99

Formula 10-100

Formula 10-101

Formula 10-102

Formula 10-103

Formula 10-104








Formula 10-105

Formula 10-106

Formula 10-107


Formula 10-108

-continued




-continued


Formula 10-109




Formula 10-110




Formula 10-111




Formula 10-112




Formula 10-113



Formula 10-114



Formula 10-115



Formula 10-116

Formula 10-117

Formula 10-118

Formula 10-119


Formula 10-120

Formula 10-121


Formula 10-122




-continued




Formula 10-137



Formula 10-138



Formula 10-139



Formula 10-140

[0115] In Formulae 9-1 to 9-19 and 10-1 to 10-140,

[0116] \* indicates a binding site to a neighboring atom,

[0117] "Ph" indicates a phenyl group, and

[0118] "TMS" indicates a trimethylsilyl group.

[0119] c1 to c4 and c7 in Formula 1 respectively indicate the numbers of R<sub>1</sub> to R<sub>4</sub> and R<sub>7</sub>, and may each independently be an integer from 1 to 5. When c1 is two or more, two or more of groups R<sub>1</sub> may be identical to or different from each other. c2 to c4 and c7 are the same as described in connection with c1.

[0120] In one or more embodiments, c1 to c4 and c7 in Formula 1 may be 1 or 2, but embodiments of the present disclosure are not limited thereto.

[0121] Z<sub>1</sub> to Z<sub>4</sub> in Formula 1 may each independently be a cyano group (CN)-containing group.

[0122] The cyano group-containing group may be

[0123] a cyano group; or

[0124] a first group substituted with at least one cyano group;

[0125] the first group may be selected from a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryl group,

a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> arylthio group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.

[0126] In an embodiment, the first group may be the same as described in connection with R<sub>1</sub>. For example, the first group may be selected from —SF<sub>5</sub>, —CH<sub>3</sub>, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, —C(CD<sub>3</sub>)<sub>3</sub>, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-140, —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), and —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>), but embodiments of the present disclosure are not limited thereto.

[0127] When the cyano group-containing group is "the first group substituted with at least one a cyano group" and the first group is \*—CH<sub>3</sub>, it would be understood through the present specification that the cyano group-containing group includes \*—C(CN)<sub>3</sub>, \*—CH(CN)<sub>2</sub>, and \*—CH<sub>2</sub>(CN).

[0128] In an embodiment, the cyano group-containing group may be a cyano group.

[0129] In Formula 1, a1 to a4 indicate the numbers of \*—[(L<sub>1</sub>)<sub>b1</sub>—(R<sub>1</sub>)<sub>c1</sub>], \*—[(L<sub>2</sub>)<sub>b2</sub>—(R<sub>2</sub>)<sub>c2</sub>], \*—[(L<sub>3</sub>)<sub>b3</sub>—(R<sub>3</sub>)<sub>c3</sub>], and \*—[(L<sub>4</sub>)<sub>b4</sub>—(R<sub>4</sub>)<sub>c4</sub>], respectively, and n1, n2, n3, and n4 indicate the numbers of Z<sub>1</sub> to Z<sub>4</sub>, respectively, and may each independently be an integer from 0 to 20. When a1 is two or more, two or more groups \*—[(L<sub>1</sub>)<sub>b1</sub>—(R<sub>1</sub>)<sub>c1</sub>] may be identical to or different from each other, when a2 is two or more, two or more groups \*—[(L<sub>2</sub>)<sub>b2</sub>—(R<sub>2</sub>)<sub>c2</sub>] may be identical to or different from each other, when a3 is two or more, two or more groups \*—[(L<sub>3</sub>)<sub>b3</sub>—(R<sub>3</sub>)<sub>c3</sub>] may be identical to or different from each other, when a4 is two or more, two or more groups \*—[(L<sub>4</sub>)<sub>b4</sub>—(R<sub>4</sub>)<sub>c4</sub>] may be identical to or different from each other, when n1 is two or more, two or more groups Z<sub>1</sub> may be identical to or different from each other, when n2 is two or more, two or more groups Z<sub>2</sub> may be identical to or different from each other, when n3 is two or more, two or more groups Z<sub>3</sub> may be identical to or different from each other, and when n4 is two or more, two or more groups Z<sub>4</sub> may be identical to or different from each other.

[0130] In Formula 1, i) two of a plurality of neighboring groups R<sub>1</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, ii) two of a plurality of neighboring groups R<sub>2</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, iii) two of a plurality of neighboring groups R<sub>3</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, iv) two of a plurality of neighboring groups R<sub>4</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, v) two or more selected from groups R<sub>1</sub> to R<sub>4</sub>, and R<sub>7</sub> and R<sub>8</sub> may optionally be linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group.

[0131] For example, in Formula 1, i) a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, formed by bonding

two of a plurality of neighboring groups  $R_1$ , ii) a substituted or unsubstituted  $C_5$ - $C_{30}$  carbocyclic group or a substituted or unsubstituted  $C_1$ - $C_{30}$  heterocyclic group, formed by bonding two of a plurality of neighboring groups  $R_2$ , iii) a substituted or unsubstituted  $C_5$ - $C_{30}$  carbocyclic group or a substituted or unsubstituted  $C_1$ - $C_{30}$  heterocyclic group, formed by bonding two of a plurality of neighboring groups  $R_3$ , iv) a substituted or unsubstituted  $C_5$ - $C_{30}$  carbocyclic group or a substituted or unsubstituted  $C_1$ - $C_{30}$  heterocyclic group, formed by bonding two of a plurality of neighboring groups  $R_4$ , and v) a substituted or unsubstituted  $C_5$ - $C_{30}$  carbocyclic group or a substituted or unsubstituted  $C_1$ - $C_{30}$  heterocyclic group, formed by bonding two or more selected from  $R_1$  to  $R_4$ ,  $R_7$ , and  $R_8$ , may each independently be selected from:

**[0132]** a pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a bicycloheptane group, a bicyclo-octane group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group; and

**[0133]** a pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a bicycloheptane group, a bicyclo-octane group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group, each substituted with at least one selected from at least one  $R_{10a}$ ;

**[0134]** but embodiments of the present disclosure are not limited thereto.

**[0135]**  $R_{10a}$  may be the same as described in connection with  $R_1$ .

**[0136]** "An azabenzothiophene, an azabenzofuran, an azaindene, an azaindole, an azabenzosilole, an azadibenzothiophene, an azadibenzofuran, an azafluorene, an azacarbazole, and an azadibenzosilole" each have the same ring system as "a benzothiophene, a benzofuran, an indene, an indole, a benzosilole, a dibenzothiophene, a dibenzofuran, a fluorene, a carbazole, and a dibenzosilole," respectively, and each further contain a hetero ring in which at least one of ring-forming carbon atoms is substituted with nitrogen.

**[0137]** In Formula 1,

**[0138]** i) when  $X_{51}$  is O, S, C(=O), or N, the sum of  $n_1$ ,  $n_2$ ,  $n_3$ , and  $n_4$  may be 1 or more (for example, 1, 2, 3, 4, or 5),

**[0139]** ii) when  $X_{51}$  is  $N[(L_7)_{b7}-(R_7)_{c7}]$ ,  $C(R_7)$ ,  $Si(R_7)$ , or  $Ge(R_7)$ ,  $R_7$  may be a cyano group-containing group or the sum of  $n_1$ ,  $n_2$ ,  $n_3$ , and  $n_4$  may be 1 or more (for example, 1, 2, 3, 4, or 5), and

**[0140]** iii) when  $X_{51}$  is  $C(R_7)(R_8)$ ,  $Si(R_7)(R_8)$ , or  $Ge(R_7)(R_8)$ , at least one selected from  $R_7$  and  $R_8$  may

be a cyano group-containing group or the sum of  $n_1$ ,  $n_2$ ,  $n_3$ , and  $n_4$  may be 1 or more (for example, 1, 2, 3, 4, or 5).

**[0141]** That is, the organometallic compound represented by Formula 1 essentially includes at least one cyano group-containing group as defined herein.

**[0142]** In an embodiment, the sum of  $n_1$ ,  $n_2$ ,  $n_3$ , and  $n_4$  in Formula 1 may be 1, 2, 3, or 4, for example, 1 or 2. That is, the number of cyano group-containing groups included in Formula 1 may be 1, 2, 3, or 4, for example, 1 or 2, but embodiments of the present disclosure are not limited thereto.

**[0143]** In one or more embodiments, in Formula 1,

**[0144]** i)  $n_1=n_2=n_3=0$ , and  $n_4=1$ ,

**[0145]** ii)  $n_1=n_2=n_4=0$ , and  $n_3=1$ ,

**[0146]** iii)  $n_1=n_3=n_4=0$ , and  $n_2=1$ ,

**[0147]** iv)  $n_2=n_3=n_4=0$ , and  $n_1=1$ ,

**[0148]** v)  $n_1=n_2=0$ , and  $n_3=n_4=1$ ,


**[0149]** vi)  $n_2=n_3=0$ , and  $n_1=n_4=1$ ,

**[0150]** vii)  $n_2=n_4=0$ , and  $n_1=n_3=1$ , or

**[0151]** viii)  $n_1=n_3=0$ , and  $n_2=n_4=1$ , but embodiments of the present disclosure are not limited thereto.


**[0152]** In one or more embodiments, in Formula 1,

**[0153]** i)  $X_1$  is a chemical bond, and a moiety represented by




may be a group represented by Formula CY1-B, or

**[0154]** ii)  $X_1$  may be O, S,  $N(R')$ ,  $P(R')$ ,  $B(R')$ ,  $C(R')(R'')$ ,  $Si(R')(R'')$ , or  $N(R')(R'')$ , and a moiety represented by




may be a group represented by Formula CY1-A:

Formula CY1-A




-continued




[0155] In Formulae CY1-A and CY1-B,  $Y_1$ ,  $CY_1$ ,  $L_1$ ,  $b_1$ ,  $R_1$ ,  $c_1$ ,  $a_1$ ,  $Z_1$ , and  $n_1$  are the same as described above,  $Y_2$  and  $Y_6$  may each independently be N or C; and a bond between  $Y_1$  and  $Y_2$ , a bond between  $Y_1$  and  $Y_6$  and a bond between  $Y_6$  and  $Y_2$  may each be a chemical bond (for example, a single bond, a double bond, or a bond constituting a carbene ligand, or the like).


[0156] In one or more embodiments, in Formula 1, a moiety represented by




may be a group represented by Formulae CY1-1 to CY1-40:




Formula CY1-1




Formula CY1-2




Formula CY1-3




Formula CY1-4




Formula CY1-5




Formula CY1-6




Formula CY1-7



Formula CY1-8




Formula CY1-9




Formula CY1-10

-continued




Formula CY1-11

-continued




Formula CY1-12


Formula CY1-16




Formula CY1-13




Formula CY1-17




Formula CY1-14




Formula CY1-18




Formula CY1-15



Formula CY1-19




Formula CY1-20




Formula CY1-21


-continued




Formula CY1-22




Formula CY1-23




Formula CY1-24



Formula CY1-25




Formula CY1-26




Formula CY1-27


-continued




Formula CY1-28




Formula CY1-29




Formula CY1-30



Formula CY1-31




Formula CY1-32




Formula CY1-33


-continued




Formula CY1-34




Formula CY1-35




Formula CY1-36




Formula CY1-37



Formula CY1-38



Formula CY1-39



Formula CY1-40

[0157] In Formulae CY1-1 to CY1-40,

[0158]  $Y_1$ ,  $R_1$ ,  $Z_1$ , and  $n_1$  are the same as described above,  $n_1$  is 0, 1, or 2,

[0159]  $X_{19}$  is  $C(R_{19a})(R_{19b})$ ,  $N[(L_{19})_{b19}-(R_{19})_{c19}]$ , O, S, or  $Si(R_{19a})(R_{19b})$ ,

[0160]  $L_{19}$  may be the same as explained in connection with  $L_1$ ,

[0161]  $b_{19}$  and  $c_{19}$  are the same as described in connection with  $b_1$  and  $c_1$ ,

[0162]  $R_{11}$  to  $R_{19}$ ,  $R_{19a}$ , and  $R_{19b}$  may be the same as described in connection with  $R_1$ ,

[0163]  $a_{12}$  may be an integer from 0 to 2,

[0164]  $a_{13}$  may be an integer from 0 to 3,

[0165]  $a_{14}$  may be an integer from 0 to 4,

[0166]  $a_{15}$  may be an integer from 0 to 5,


[0167]  $a_{16}$  may be an integer from 0 to 6,

[0168]  $a_{17}$  may be an integer from 0 to 7,


[0169] \* indicates a binding site to M in Formula 1, and

[0170] \* indicates a binding site to  $CY_5$  in Formula 1.


[0171] In one or more embodiments, in Formula 1, a moiety represented by




may be a group represented by Formulae CY2-1 to CY2-20:



Formula CY2-1




Formula CY2-2




Formula CY2-3

-continued




Formula CY2-4


-continued




Formula CY2-10




Formula CY2-5




Formula CY2-11




Formula CY2-6




Formula CY2-12




Formula CY2-7




Formula CY2-13




Formula CY2-8



Formula CY2-14




Formula CY2-9




Formula CY2-15


-continued




Formula CY2-16




Formula CY2-17



Formula CY2-18




Formula CY2-19




Formula CY2-20


[0182] In one or more embodiments, in Formula 1, a moiety represented by




may be a group represented by one of Formulae CY3-1 to CY3-12:




Formula CY3-1




Formula CY3-2




Formula CY3-3



Formula CY3-4



Formula CY3-5



Formula CY3-6

[0172] In Formulae CY2-1 to CY2-20,

[0173]  $R_2$ ,  $Z_2$ , and  $n_2$  may be the same as described above,  $n_2$  may be 0, 1, or 2,

[0174]  $X_{51}$  in Formulae CY2-1 to CY2-4 may be O, S, N- $[(L_7)_{b7}-(R_7)_{c7}]$ , C( $R_7$ )( $R_8$ ), Si( $R_7$ )( $R_8$ ), Ge( $R_7$ )( $R_8$ ), or C(=O),

[0175]  $X_{51}$  in Formulae CY2-5 to CY2-20 may be N, C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ),

[0176]  $L_7$ ,  $b_7$ ,  $R_7$ , and  $c_7$  may be the same as described above,

[0177]  $a_{22}$  may be an integer from 0 to 2,


[0178]  $a_{23}$  may be an integer from 0 to 3,

[0179] indicates a binding site to  $CY_1$  in Formula 1,


[0180] \*' indicates a binding site to M in Formula 1, and

[0181] \*'' indicates a binding site to  $CY_3$  in Formula 1.


-continued




Formula CY3-7




Formula CY3-8




Formula CY3-9



Formula CY3-10



Formula CY3-11



Formula CY3-12

[0183] In Formulae CY3-1 to CY3-12,

[0184]  $X_3$ ,  $R_3$ ,  $Z_3$ , and  $n_3$  may be the same as described above,  $n_3$  is 0, 1, or 2,

[0185]  $X_{39}$  may be  $C(R_{39a})(R_{39b})$ ,  $N[(L_{39})_{b39}-(R_{39})_{c39}]$ , O, S, or  $Si(R_{39a})(R_{39b})$ ,

[0186]  $L_{39}$  may be the same as explained in connection with  $L_3$ ;

[0187]  $b_{39}$  and  $c_{39}$  may be the same as described in connection with  $b_3$  and  $c_3$

[0188]  $R_{39a}$  and  $R_{39b}$  may be the same as described in connection with  $R_3$ ,

[0189]  $a_{32}$  may be an integer from 0 to 2,

[0190]  $a_{33}$  may be an integer from 0 to 3,

[0191]  $a_{34}$  may be an integer from 0 to 4,


[0192]  $a_{35}$  may be an integer from 0 to 5,

[0193] \* indicates a binding site to  $CY_4$  in Formula 1,


[0194] \*' indicates a binding site to M in Formula 1, and

[0195] \*'' indicates a binding site to  $CY_2$  in Formula 1.


[0196] In one or more embodiments, in Formula 1, a moiety represented by




may be a group represented by one of Formulae CY4-1 to CY4-26:




Formula CY4-1




Formula CY4-2



Formula CY4-3




Formula CY4-4




Formula CY4-5


-continued




Formula CY4-6




Formula CY4-7




Formula CY4-8




Formula CY4-9



Formula CY4-10




Formula CY4-11




-continued


Formula CY4-12




Formula CY4-13




Formula CY4-14



Formula CY4-15




Formula CY4-16




Formula CY4-17


-continued




Formula CY4-18




Formula CY4-19




Formula CY4-20



Formula CY4-21




Formula CY4-22




Formula CY4-23


-continued



Formula CY4-24



Formula CY4-25



Formula CY4-26

[0197] In Formulae CY4-1 to CY4-26,

[0198]  $X_4$ ,  $R_4$ ,  $Z_4$ , and  $n_4$  may be the same as described above,  $n_4$  may be 0, 1, or 2,

[0199]  $X_{49}$  may be  $C(R_{49a})(R_{49b})$ ,  $N[(L_{49})_{b49}-(R_{49})_{c49}]$ , O, S, or  $Si(R_{49a})(R_{49b})$ ,

[0200]  $L_{49}$  may be the same as explained in connection with  $L_4$ ;

[0201]  $b_{49}$  and  $c_{49}$  may be the same as described in connection with  $b_4$  and  $c_4$ ,

[0202]  $R_{41}$  to  $R_{49}$ ,  $R_{49a}$ , and  $R_{49b}$  may be the same as described in connection with  $R_4$ ,

[0203]  $a_{42}$  may be an integer from 0 to 2,

[0204]  $a_{43}$  may be an integer from 0 to 3,

[0205]  $a_{44}$  may be an integer from 0 to 4,

[0206]  $a_{45}$  may be an integer from 0 to 5,


[0207]  $a_{46}$  may be an integer from 0 to 6,

[0208] \* indicates a binding site to  $CY_3$  in Formula 1, and

[0209] \*<sup>1</sup> indicates a binding site to M in Formula 1.


[0210] In one or more embodiments, regarding Formula 1,

[0211] a moiety represented by




may be a group represented by Formulae CY1(1) to CY1(18) and CY1-CN(1) to CY1-CN(12), and(or)

[0212] a moiety represented by




may be a group represented by Formulae CY2(1) to CY2(20) and CY2-CN(1) to CY2-CN(15), and(or)

[0213] a moiety represented by



may be a group represented by Formulae CY3(1) to CY3(12) and CY3-CN(1) to CY3-CN(8), and(or)


[0214] a moiety represented by




may be a group represented by Formulae CY4(1) to CY4(10) and CY4-CN(1) to CY4-CN(12), but embodiments of the present disclosure are not limited thereto:

-continued


Formula CY1(3)




Formula CY1(4)




Formula CY1(5)




Formula CY1(6)




Formula CY1(7)




Formula CY1(8)




Formula CY1(9)




Formula CY1(1)




Formula CY1(2)




-continued




Formula CY1(10)




Formula CY1(11)




Formula CY1(12)



Formula CY1(13)




Formula CY1(14)




Formula CY1(15)


-continued




Formula CY1(16)




Formula CY1(17)




Formula CY1(18)




Formula CY1-CN(1)



Formula CY1-CN(2)




Formula CY1-CN(3)




Formula CY1-CN(4)


-continued




Formula CY1-CN(5)




Formula CY1-CN(6)




Formula CY1-CN(7)




Formula CY1-CN(8)



Formula CY1-CN(9)




Formula CY1-CN(10)




Formula CY1-CN(11)


-continued




Formula CY1-CN(12)




Formula CY2(1)




Formula CY2(2)




Formula CY2(3)



Formula CY2(4)




Formula CY2(5)




Formula CY2(6)


-continued




Formula CY2(7)




Formula CY2(8)




Formula CY2(9)




Formula CY2(10)



Formula CY2(11)




Formula CY2(12)




Formula CY2(13)


-continued




Formula CY2(14)




Formula CY2(15)




Formula CY2(16)




Formula CY2(17)



Formula CY2(18)




Formula CY2(19)




Formula CY2(20)


-continued




Formula CY2-CN(1)




Formula CY2-CN(2)




Formula CY2-CN(3)



Formula CY2-CN(4)




Formula CY2-CN(5)




Formula CY2-CN(6)


-continued




Formula CY2-CN(7)




Formula CY2-CN(8)




Formula CY2-CN(9)




Formula CY2-CN(10)



Formula CY2-CN(11)




Formula CY2-CN(12)




Formula CY2-CN(13)


-continued




Formula CY2-CN(14)




Formula CY2-CN(15)




Formula CY3(1)




Formula CY3(2)



Formula CY3(3)




Formula CY3(4)




Formula CY3(5)


-continued




Formula CY3(6)




Formula CY3(7)




Formula CY3(8)




Formula CY3(9)



Formula CY3(10)




Formula CY3(11)




Formula CY3(12)


-continued




Formula CY3-CN(1)




Formula CY3-CN(2)




Formula CY3-CN(3)




Formula CY3-CN(4)



Formula CY3-CN(5)




Formula CY3-CN(6)




Formula CY3-CN(7)


-continued




Formula CY3-CN(8)




Formula CY4(1)




Formula CY4(2)




Formula CY4(3)




Formula CY4(4)



Formula CY4(5)




Formula CY4(6)




Formula CY4(7)


-continued




Formula CY4(8)




Formula CY4(9)




Formula CY4(10)




Formula CY4-CN(1)



Formula CY4-CN(2)




Formula CY4-CN(3)




Formula CY4-CN(4)


-continued




Formula CY4-CN(5)




Formula CY4-CN(6)




Formula CY4-CN(7)




Formula CY4-CN(8)



Formula CY4-CN(9)




Formula CY4-CN(10)



Formula CY4-CN(11)

-continued

Formula CY4-CN(12)



[0215] In Formulae CY1(1) to CY1(18), CY1-CN(1) to CY1-CN(12), CY2(1) to CY2(20), CY2-CN(1) to CY2-CN(15), CY3(1) to CY3(12), CY3-CN(1) to CY3-CN(8), CY4(1) to CY4(10), and CY4-CN(1) to CY4-CN(12),

[0216]  $X_2$  to  $X_4$ ,  $Y_1$ ,  $R_1$  to  $R_4$ , and  $Z_1$  to  $Z_4$  may be the same as described above,

[0217]  $R_{1a}$  to  $R_{1d}$  may be the same as described in connection with  $R_1$ ,

[0218]  $X_{39}$  may be  $C(R_{39a})(R_{39b})$ ,  $N[(L_{39})_{b39}-(R_{39})_{c39}]$ , O, S, or  $Si(R_{39a})(R_{39b})$ ,

[0219]  $L_{39}$  may be the same as explained in connection with  $L_3$ ;

[0220]  $b_{39}$  and  $c_{39}$  may be the same as described in connection with  $b_3$  and  $c_3$ ,

[0221]  $R_{3a}$ ,  $R_{3b}$ ,  $R_{39a}$ , and  $R_{39b}$  may be the same as described in connection with  $R_3$ ,

[0222]  $R_{4a}$  to  $R_{4d}$  may be the same as described in connection with  $R_4$ ,

[0223]  $R_1$  to  $R_4$ ,  $R_{1a}$  to  $R_{1d}$ ,  $R_{3a}$ ,  $R_{3b}$ , and  $R_{4a}$  to  $R_{4d}$  may each not be hydrogen,

[0224] \* indicates a binding site to M in Formula 1,

[0225] \* in Formulae CY1(1) to CY1(18) and CY1-CN(1) to CY1-CN(12) indicates a binding site to  $CY_5$  in Formula 1,

[0226] \* in Formulae CY2(1) to CY2(20) and CY2-CN(1) to CY2-CN(15) indicates a binding site to  $CY_1$  in Formula 1,






[0227] \* in Formulae CY2(1) to CY2(20) and CY2-CN(1) to CY2-CN(15) indicates a binding site to  $CY_3$  in Formula 1,

[0228] \* in Formulae CY3(1) to CY3(12) and CY3-CN(1) to CY3-CN(8) indicates a binding site to  $CY_2$  in Formula 1,

[0229] \* in Formulae CY3(1) to CY3(12) and CY3-CN(1) to CY3-CN(8) indicates a binding site to  $CY_4$  in Formula 1, and

[0230] \* in Formulae CY4(1) to CY4(10) and CY4-CN(1) to CY4-CN(12) indicates a binding site to  $CY_3$  in Formula 1.

[0231] For example, the organometallic compound may be one of Compounds 1 to 190, but embodiments of the present disclosure are not limited thereto:



1


2

3


4

5


-continued




6




7



8




9




10


-continued




11




12



13




14



15


16

-continued




17


-continued




22




18




23




19




24




20



25




21




26

-continued




27


-continued




31




28




32




29



33




30




34

-continued




35


-continued




40




36




41




37




42



38




43




39


-continued




44



45




46




47


-continued




48




49



50




51




52


-continued




53




54



55




56




57


-continued




58




59



60




61




62

-continued




63


-continued




67




64




68




65



69




66




70

-continued




71


-continued




75




72




76




73



77




74




78

-continued




79

-continued




83


80




84




81




85




82




86




-continued




-continued




88



92





89




93

90




-continued

94




-continued


98




95




99




96




100




97










101




-continued










-continued




-continued



-continued




-continued




118

-continued




122


119




120



123




121



124


-continued

125





-continued

128





129

126




130

127




-continued

131





-continued

134





135

132




136

133




137




-continued

138




-continued


142




139




143




140




144



141




145




-continued

146




-continued


149




147




150




148




151




-continued




-continued




153




156



154




157




-continued

158




-continued


161




162




159




163



160




164




-continued

165




-continued


168




166




169




167




170




-continued




-continued




172




176




173




174




177




-continued




-continued




179




182



180




183




-continued

184




-continued


187




185




188



186




189



-continued

190



[0232] Formula 1 has a 5-membered ring represented by  $CY_5$ , and a cyclometalated ring formed by  $CY_5$ ,  $CY_2$ ,  $CY_3$ , and M in Formula 1 is a 6-membered ring. Due to this structure, a binding angle between tetradentate ligand and metal in Formula 1 is stable, and accordingly, the molecular stability of the organometallic compound represented by Formula 1 may be improved.

[0233] Also, in Formula 1, i) when  $X_{51}$  is O, S, C(=O), or N, the sum of n1, n2, n3, and n4 is 1 or more, ii) when  $X_{51}$  is N[( $L_7$ ) $b_7$ -( $R_7$ ) $C_7$ ], C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ),  $R_7$  is a cyano group-containing group or the sum of n1, n2, n3, and n4 is 1 or more, and iii) when  $X_{51}$  is C( $R_7$ )( $R_8$ ), Si( $R_7$ )( $R_8$ ), or Ge( $R_7$ )( $R_8$ ), at least one selected from  $R_7$  and  $R_8$  is a cyano group-containing group or the sum of n1, n2, n3, and n4 is 1 or more. That is, the organometallic compound represented by Formula 1 essentially includes at least one cyano group-containing group as defined herein. Accordingly, charge-transfer characteristics of the organometallic compound are improved, and thus, an electronic device, for example, an organic light-emitting device, in which the organometallic compound is used, may have an improved luminescent efficiency and an easily controllable-emission wavelength band.

[0234] For example, the highest occupied molecular orbital (HOMO), lowest unoccupied molecular orbital (LUMO), singlet ( $S_1$ ), and triplet ( $T_1$ ) energy levels of Compounds 61, 123, 124, 128, and 158 were calculated by using a DFT method of the Gaussian program [structurally optimized at the level of B3LYP, 6-31G(d,p)]. The evaluation results are shown in Table 1 below.

TABLE 1

Compound No.	HOMO (eV)	LUMO (eV)	$T_1$ energy level (eV)
61	-5.014	-2.453	1.961
123	-4.920	-2.419	1.906
124	-4.866	-2.396	1.878
128	-4.866	-2.318	1.977
158	-4.617	-2.438	1.639

[0235] From the data in Table 1, it is confirmed that the organometallic compound represented by Formula 1 has

such electric characteristics that are suitable for use in an electric device, for example, for use as a dopant for an organic light-emitting device.

[0236] Synthesis methods of the organometallic compound represented by Formula 1 may be recognizable by one of ordinary skill in the art by referring to Synthesis Examples provided below.

[0237] The organometallic compound represented by Formula 1 is suitable for use in an organic layer of an organic light-emitting device, for example, for use as a dopant in an emission layer of the organic layer.

[0238] Thus, another aspect of the present disclosure provides an organic light-emitting device that includes:

[0239] a first electrode;

[0240] a second electrode; and

[0241] an organic layer that is disposed between the first electrode and the second electrode,

[0242] wherein the organic layer includes an emission layer and at least one organometallic compound represented by Formula 1.

[0243] The organic light-emitting device may have, due to the inclusion of an organic layer including the organometallic compound represented by Formula 1, a low driving voltage, high efficiency, high power, high quantum efficiency, a long lifespan, a low roll-off ratio, and excellent color purity.

[0244] The organometallic compound of Formula 1 may be used between a pair of electrodes of an organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included in the emission layer. In this regard, the organometallic compound may act as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host).

[0245] The expression “(an organic layer) includes at least one of organometallic compounds” used herein may include a case in which “(an organic layer) includes identical organometallic compounds represented by Formula 1” and a case in which “(an organic layer) includes two or more different organometallic compounds represented by Formula 1.”

[0246] For example, the organic layer may include, as the organometallic compound, only Compound 1. In this regard, Compound 1 may be included in an emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include, as the organometallic compound, Compound 1 and Compound 2. In this regard, Compound 1 and Compound 2 may be included in an identical layer (for example, Compound 1 and Compound 2 all may be included in an emission layer).

[0247] The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode; or the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

[0248] In an embodiment, in the organic light-emitting device, the first electrode is an anode, and the second electrode is a cathode, and the organic layer further includes a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode, wherein the hole transport region includes a hole injection layer, a hole transport layer, an electron blocking

layer, or any combination thereof, and wherein the electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

[0249] The term “organic layer” as used herein refers to a single layer and/or a plurality of layers disposed between the first electrode and the second electrode of the organic light-emitting device. The “organic layer” may include, in addition to an organic compound, an organometallic complex including metal.

[0250] The FIG. 1s a schematic view of an organic light-emitting device **10** according to an embodiment. Hereinafter, the structure of an organic light-emitting device according to an embodiment and a method of manufacturing an organic light-emitting device according to an embodiment will be described in connection with the FIGURE. The organic light-emitting device **10** includes a first electrode **11**, an organic layer **15**, and a second electrode **19**, which are sequentially stacked.

[0251] A substrate may be additionally located under the first electrode **11** or above the second electrode **19**. For use as the substrate, any substrate that is used in general organic light-emitting devices may be used, and the substrate may be a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.

[0252] The first electrode **11** may be formed by depositing or sputtering a material for forming the first electrode **11** on the substrate. The first electrode **11** may be an anode. The material for forming the first electrode **11** may be selected from materials with a high work function to facilitate hole injection. The first electrode **11** may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode may be, for example, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO<sub>2</sub>), and zinc oxide (ZnO). In one or more embodiments, magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be used as the material for forming the first electrode.

[0253] The first electrode **11** may have a single-layered structure or a multi-layered structure including two or more layers. For example, the first electrode **11** may have a three-layered structure of ITO/Ag/ITO, but the structure of the first electrode **110** is not limited thereto.

[0254] The organic layer **15** is located on the first electrode **11**.

[0255] The organic layer **15** may include a hole transport region, an emission layer, and an electron transport region.

[0256] The hole transport region may be disposed between the first electrode **11** and the emission layer.

[0257] The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof.

[0258] The hole transport region may include only either a hole injection layer or a hole transport layer. In one or more embodiments, the hole transport region may have a hole injection layer/hole transport layer structure or a hole injection layer/hole transport layer/electron blocking layer structure, which are sequentially stacked in this stated order from the first electrode **11**.


[0259] A hole injection layer may be formed on the first electrode **11** by using one or more suitable methods selected from vacuum deposition, spin coating, casting, or Langmuir-Blodgett (LB) deposition.

[0260] When a hole injection layer is formed by vacuum deposition, the deposition conditions may vary depending on a material that is used to form the hole injection layer, and the structure and thermal characteristics of the hole injection layer. For example, the deposition conditions may include a deposition temperature of about 100 to about 500° C., a vacuum pressure of about 10<sup>-8</sup> to about 10<sup>-3</sup> torr, and a deposition rate of about 0.01 to about 100 Å/sec. However, the deposition conditions are not limited thereto.

[0261] When the hole injection layer is formed using spin coating, coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For example, a coating speed may be from about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a temperature at which a heat treatment is performed to remove a solvent after coating may be from about 80° C. to about 200° C. However, the coating conditions are not limited thereto.


[0262] Conditions for forming a hole transport layer and an electron blocking layer may be understood by referring to conditions for forming the hole injection layer.

[0263] The hole transport region may include at least one selected from m-MTDATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, Spiro-TPD, Spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4',4"-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrenesulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below:




m-MTDATA

-continued




TDATA


-continued




$\beta$ -NPB




TPD




2-TNATA




Spiro-TPD




Spiro-NPB




NPB




methylated NPB



Formula 201



Formula 202



[0264]  $Ar_{101}$  and  $Ar_{102}$  in Formula 201 may each independently be selected from:

[0265] a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluore-

nylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group; and

[0266] a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, or a pentacenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{60}$  alkyl group, a  $C_2$ - $C_{60}$  alkenyl group, a  $C_2$ - $C_{60}$  alkynyl group, a  $C_1$ - $C_{60}$  alkoxy group, a  $C_3$ - $C_{10}$  cycloalkyl group, a  $C_3$ - $C_{10}$  cycloalkenyl group, a  $C_1$ - $C_{10}$  heterocycloalkyl group, a  $C_1$ - $C_{10}$  heterocycloalkenyl group, a  $C_6$ - $C_{60}$  aryl group, a  $C_6$ - $C_{60}$  aryloxy group, a  $C_6$ - $C_{60}$  arylthio group, a  $C_1$ - $C_{60}$  heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0267] In Formula 201,  $x_a$  and  $x_b$  may each independently be an integer from 0 to 5, or 0, 1, or 2. For example,  $x_a$  is 1 and  $x_b$  is 0, but  $x_a$  and  $x_b$  are not limited thereto.

[0268]  $R_{101}$  to  $R_{108}$ ,  $R_{111}$  to  $R_{119}$ , and  $R_{121}$  to  $R_{124}$  in Formulae 201 and 202 may each independently be selected from:

[0269] hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{10}$  alkyl group (for example, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, and so on), and a  $C_1$ - $C_{10}$  alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, and so on);

[0270] a  $C_1$ - $C_{10}$  alkyl group and a  $C_1$ - $C_{10}$  alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, and a phosphoric acid group or a salt thereof;

[0271] a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group; and

[0272] a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{10}$  alkyl group, and a  $C_1$ - $C_{10}$  alkoxy group, but they are not limited thereto.

[0273] but embodiments of the present disclosure are not limited thereto.


[0274]  $R_{109}$  in Formula 201 may be selected from:

[0275] a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group; and

[0276] a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{20}$  alkyl group, a  $C_1$ - $C_{20}$  alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group.

[0277] According to an embodiment, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments of the present disclosure are not limited thereto:


Formula 201A



[0278]  $R_{101}$ ,  $R_{111}$ ,  $R_{112}$ , and  $R_{109}$  in Formula 201A may be understood by referring to the description provided herein.


[0279] For example, the compound represented by Formula 201, and the compound represented by Formula 202 may include compounds HT1 to HT20 illustrated below, but are not limited thereto:

HT1




-continued

HT2



HT3





-continued

-continued



HT4

HT6



HT5

HT7





-continued

-continued



HT8

HT10




HT9

HT11




-continued

HT12




-continued


HT16




HT13




HT17




HT14




HT18



HT15




HT19



-continued


HT20



[0280] A thickness of the hole transport region may be in a range of about 100 Å to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes at least one of a hole injection layer and a hole transport layer, the thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, and for example, about 100 Å to about 1,000 Å, and the thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, and for example, about 100 Å to about 1,500 Å. While not wishing to be bound by theory, it is understood that when the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.


[0281] The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties. The charge-generation material may be homogeneously or non-homogeneously dispersed in the hole transport region.

[0282] The charge-generation material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone derivative, a metal oxide, and a cyano group-containing compound, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonodimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonodimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenum oxide; and a cyano group-containing compound, such as Compound HT-D1 below, but are not limited thereto.



HT-D1

-continued



F4-TCNQ

[0283] The hole transport region may include a buffer layer.


[0284] Also, the buffer layer may compensate for an optical resonance distance depending on a wavelength of light emitted from the emission layer, and thus, efficiency of a formed organic light-emitting device may be improved.

[0285] Then, an emission layer (EML) may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, or the like. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those applied in forming the hole injection layer although the deposition or coating conditions may vary according to a compound that is used to form the emission layer.









[0286] Meanwhile, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be selected from materials for the hole transport region described above and materials for a host to be explained later. However, the material for the electron blocking layer is not limited thereto. For example, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be mCP, which will be explained later.

[0287] The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1.

[0288] The host may include at least one selected from TPBi, TBADN, ADN (also referred to as "DNA"), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:




TPBi



[0289] In one or more embodiments, the host may further include a compound represented by Formula 301 below.

Formula 301



[0290]  $Ar_{111}$  and  $Ar_{112}$  in Formula 301 may each independently be selected from:

[0291] a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group; and

[0292] a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group;

[0293]  $Ar_{113}$  to  $Ar_{116}$  in Formula 301 may each independently be selected from:

[0294] a  $C_1$ - $C_{10}$  alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group; and

[0295] a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.


[0296] g, h, i, and j in Formula 301 may each independently be an integer from 0 to 4, and may be, for example, 0, 1, or 2.

[0297] Ar<sub>113</sub> to Ar<sub>116</sub> in Formula 301 may each independently be selected from:

[0298] a C<sub>1</sub>-C<sub>10</sub> alkyl group, substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group;


[0299] a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl, a phenanthrenyl group, and a fluorenyl group;

[0300] a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group; and



[0301] but embodiments of the present disclosure are not limited thereto.

[0302] In one or more embodiments, the host may include a compound represented by Formula 302 below:



Formula 302

[0303] Ar<sub>122</sub> to Ar<sub>125</sub> in Formula 302 are the same as described in detail in connection with Ar<sub>113</sub> in Formula 301.

[0304] Ar<sub>126</sub> and Ar<sub>127</sub> in Formula 302 may each independently be a C<sub>1</sub>-C<sub>10</sub> alkyl group (for example, a methyl group, an ethyl group, or a propyl group).

[0305] k and l in Formula 302 may each independently be an integer from 0 to 4. For example, k and l may be 0, 1, or 2.

[0306] When the organic light-emitting device is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. In one or more embodiments, due to a stacked structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light.

[0307] When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts by weight to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.

[0308] A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. While not wishing to be bound by theory, it is understood that when the thickness of the emission layer is within this range, excellent light-emission characteristics may be obtained without a substantial increase in driving voltage.


[0309] Then, an electron transport region may be located on the emission layer.

[0310] The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.


[0311] For example, the electron transport region may have a hole blocking layer/electron transport layer/electron injection layer structure or an electron transport layer/electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.

[0312] Conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer which constitute the electron transport region may be understood by referring to the conditions for forming the hole injection layer.

[0313] When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen, and BAQ but embodiments of the present disclosure are not limited thereto.





BCP




Bphen

[0314] A thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. While not wishing to be bound by theory, it is understood that when the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have improved hole blocking ability without a substantial increase in driving voltage.


[0315] The electron transport layer may further include at least one selected from BCP, Bphen, Alq<sub>3</sub>, BAlq, TAZ, and NTAZ.

Alq<sub>3</sub>


ET1




BAlq




ET2



TAZ



NTAZ




ET3

[0316] In one or more embodiments, the electron transport layer may include at least one of ET1 and ET25, but are not limited thereto:


-continued

ET4




-continued


ET7




ET5




ET8



ET6




ET9




-continued

ET10




-continued


ET14




ET11




ET15




ET12



ET13




ET16




-continued

ET17




-continued


ET20




ET18




ET19




ET21



ET22



-continued



ET23


ET24

ET25

[0317] A thickness of the electron transport may be in a range of about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron transport layer is within the range described above, the electron transport layer may have satisfactory electron transport characteristics without a substantial increase in driving voltage.

[0318] Also, the electron transport layer may further include, in addition to the materials described above, a metal-containing material.

[0319] The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium quinolate, LiQ) or ET-D2.



ET-D1

ET-D2

[0320] The electron transport region may include an electron injection layer (EIL) that promotes flow of electrons from the second electrode 19 thereto.

[0321] The electron injection layer may include at least one selected from LiF, NaCl, CsF, Li<sub>2</sub>O, and BaO.

[0322] A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron injection layer is within the range described above, the electron injection layer may have satisfactory electron injection characteristics without a substantial increase in driving voltage.

[0323] The second electrode 19 is located on the organic layer 15. The second electrode 19 may be a cathode. A material for forming the second electrode 19 may be selected from metal, an alloy, an electrically conductive compound, and a combination thereof, which have a relatively low work function. For example, lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be used as a material for forming the second electrode 19. In one or more embodiments, to manufacture a top-emission type light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode 19.

[0324] Hereinbefore, the organic light-emitting device has been described with reference to the FIGURE, but embodiments of the present disclosure are not limited thereto.

[0325] Another aspect of the present disclosure provides a diagnostic composition including at least one organometallic compound represented by Formula 1.

[0326] The organometallic compound represented by Formula 1 provides high luminescent efficiency. Accordingly, a

diagnostic composition including the organometallic compound may have high diagnostic efficiency.

[0327] The diagnostic composition may be used in various applications including a diagnosis kit, a diagnosis reagent, a biosensor, and a biomarker.

[0328] The term “C<sub>1</sub>-C<sub>60</sub> alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and non-limiting examples thereof include a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. The term “C<sub>1</sub>-C<sub>60</sub> alkylene group” as used herein refers to a divalent group having the same structure as the C<sub>1</sub>-C<sub>60</sub> alkyl group.

[0329] The term “C<sub>1</sub>-C<sub>60</sub> alkoxy group” as used herein refers to a monovalent group represented by —OA<sub>101</sub> (wherein A<sub>101</sub> is the C<sub>1</sub>-C<sub>60</sub> alkyl group), and non-limiting examples thereof include a methoxy group, an ethoxy group, and an iso-propyloxy group.

[0330] The term “C<sub>2</sub>-C<sub>60</sub> alkenyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon double bond in the middle or at the terminus of the C<sub>2</sub>-C<sub>60</sub> alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C<sub>2</sub>-C<sub>60</sub> alkenylene group” as used herein refers to a divalent group having the same structure as the C<sub>2</sub>-C<sub>60</sub> alkenyl group.

[0331] The term “C<sub>2</sub>-C<sub>60</sub> alkynyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon triple bond in the middle or at the terminus of the C<sub>2</sub>-C<sub>60</sub> alkyl group, and examples thereof include an ethynyl group, and a propynyl group. The term “C<sub>2</sub>-C<sub>60</sub> alkynylene group” as used herein refers to a divalent group having the same structure as the C<sub>2</sub>-C<sub>60</sub> alkynyl group.

[0332] The term “C<sub>3</sub>-C<sub>10</sub> cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C<sub>3</sub>-C<sub>10</sub> cycloalkylene group” as used herein refers to a divalent group having the same structure as the C<sub>3</sub>-C<sub>10</sub> cycloalkyl group.

[0333] The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuran group, and a tetrahydrothiophenyl group. The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group.

[0334] The term “C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms, that has at least one carbon-carbon double bond in the ring thereof, and that is not aromatic. Non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C<sub>3</sub>-C<sub>10</sub> cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group.

[0335] The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom selected from N, O, P, Si, and S

as a ring-forming atom, 1 to 10 carbon atoms, and that has at least one carbon-carbon double bond in its ring. Examples of the C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group are a 2,3-dihydrofuran group, and a 2,3-dihydrothiophenyl group. The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group.

[0336] The term “C<sub>6</sub>-C<sub>60</sub> aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term “C<sub>6</sub>-C<sub>60</sub> arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Non-limiting examples of the C<sub>6</sub>-C<sub>60</sub> aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C<sub>6</sub>-C<sub>60</sub> aryl group and the C<sub>6</sub>-C<sub>60</sub> arylene group each include two or more rings, the rings may be fused to each other.

[0337] The term “C<sub>1</sub>-C<sub>60</sub> heteroaryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, and 1 to 60 carbon atoms. The term “C<sub>1</sub>-C<sub>60</sub> heteroarylene group” as used herein refers to a divalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, and S as a ring-forming atom, and 1 to 60 carbon atoms. Non-limiting examples of the C<sub>1</sub>-C<sub>60</sub> heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C<sub>1</sub>-C<sub>60</sub> heteroaryl group and the C<sub>1</sub>-C<sub>60</sub> heteroarylene group each include two or more rings, the rings may be fused to each other.

[0338] The term “C<sub>6</sub>-C<sub>60</sub> aryloxy group” used herein indicates —OA<sub>102</sub> (wherein A<sub>102</sub> is the C<sub>6</sub>-C<sub>60</sub> aryl group), and a C<sub>6</sub>-C<sub>60</sub> arylthio group used herein indicates —SA<sub>103</sub> (wherein A<sub>103</sub> is the C<sub>6</sub>-C<sub>60</sub> aryl group).

[0339] The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, having only carbon atoms as ring-forming atoms, and that is not aromatic in its entire molecular structure. Examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

[0340] The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group (for example, having 2 to 60 carbon atoms) having two or more rings condensed to each other, having a heteroatom selected from N, O, P, Si, and S, other than carbon atoms, as a ring-forming atom, and that is not aromatic in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed heteropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

[0341] The term “C<sub>5</sub>-C<sub>30</sub> carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group

having, as a ring-forming atom, 5 to 30 carbon atoms only. The C<sub>5</sub>-C<sub>30</sub> carbocyclic group may be a monocyclic group or a polycyclic group.

[0342] The term “C<sub>1</sub>-C<sub>30</sub> heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom selected from N, O, Si, P, and S other than 1 to 30 carbon atoms. The C<sub>1</sub>-C<sub>30</sub> heterocyclic group may be a monocyclic group or a polycyclic group.

[0343] At least one of substituents of the substituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, substituted C<sub>2</sub>-C<sub>30</sub> heterocyclic group, substituted C<sub>1</sub>-C<sub>60</sub> alkyl group, substituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, substituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, substituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, substituted C<sub>6</sub>-C<sub>60</sub> aryl group, substituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, substituted C<sub>6</sub>-C<sub>60</sub> arylthio group, substituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, substituted monovalent non-aromatic condensed polycyclic group, and substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

[0344] deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, and a C<sub>1</sub>-C<sub>60</sub> alkoxy group;

[0345] a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, and a C<sub>1</sub>-C<sub>60</sub> alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>11</sub>)(Q<sub>12</sub>), —Si(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —B(Q<sub>16</sub>)(Q<sub>17</sub>), and —P(=O)(Q<sub>18</sub>)(Q<sub>19</sub>);

[0346] a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

[0347] a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a

C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>21</sub>)(Q<sub>22</sub>), —Si(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —B(Q<sub>26</sub>)(Q<sub>27</sub>), and —P(=O)(Q<sub>28</sub>)(Q<sub>29</sub>); and

[0348] —N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>), and —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>),

[0349] wherein Q<sub>1</sub> to Q<sub>9</sub>, Q<sub>11</sub> to Q<sub>19</sub>, Q<sub>21</sub> to Q<sub>29</sub>, and Q<sub>31</sub> to Q<sub>39</sub> may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>1</sub>-C<sub>60</sub> alkyl group substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, and a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryl group substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, and a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.


[0350] When a group containing a specified number of carbon atoms is substituted with any of the groups listed in the preceding paragraph, the number of carbon atoms in the resulting “substituted” group is defined as the sum of the carbon atoms contained in the original (unsubstituted) group and the carbon atoms (if any) contained in the substituent. For example, when the term “substituted C<sub>1</sub>-C<sub>30</sub> alkyl” refers to a C<sub>1</sub>-C<sub>30</sub> alkyl group substituted with C<sub>6</sub>-C<sub>30</sub> aryl group, the total number of carbon atoms in the resulting aryl substituted alkyl group is C<sub>7</sub>-C<sub>60</sub>.





[0351] Hereinafter, a compound and an organic light-emitting device according to embodiments are described in detail with reference to Synthesis Example and Examples. However, the organic light-emitting device is not limited thereto. The wording “B was used instead of A” used in describing Synthesis Examples refers to that an identical molar equivalent of B was used in place of A.

## EXAMPLE

### Synthesis Example 1: Synthesis of Compound 123

#### [0352] Synthesis of Intermediate P2










**[0353]** 120 milliliters (mL) of tetrahydrofuran (THF) and 40 mL of distilled water were mixed with Compound P3-1 (5.3 grams (g), 20.5 millimoles, mmol), Compound P3-2 (7 g, 19.5 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (1.6 g, 1.4 mmol), and K<sub>2</sub>CO<sub>3</sub> (8.1 g, 58.6 mmol), and the mixture was stirred under reflux for 12 hours. Once the reaction was completed, the temperature was lowered to room temperature, and the organic layer was extracted therefrom with methylene chloride (MC). The combined organic extracts were dried over anhydrous magnesium sulfate (MgSO<sub>4</sub>) and filtered. The obtained filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography using MC and hexane, thereby completing the preparation of 5.8 g (73%) of Intermediate P2.

**[0354]** Synthesis of Intermediate P1

**[0355]** Intermediate P2 (5.8 g, 14.18 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (7.2 g, 28.36 mmol), PdCl<sub>2</sub>(dppf) (0.83 g, 1.1 mmol), and potassium acetate (4.2 g, 42.5 mmol) were mixed with 300 mL of toluene, and the mixture was stirred under reflux for 18 hours. The temperature was lowered down to room temperature. The organic layer was extracted therefrom with MC, and the combined organic extracts were dried over anhydrous magnesium sulfate (MgSO<sub>4</sub>) and filtered. The obtained filtrate was subjected to reduced pressure and the residue was purified by column chromatography using EA and hexane, thereby completing the preparation of 5.4 g (83%) of Intermediate P1.

**[0356]** Synthesis of Ligand 123L





**[0359]** Ligand 123L (1.2 g, 1.6 mmol) and  $K_2PtCl_4$  (0.7 g, 1.8 mmol) were mixed with 50 mL of acetic acid, and the mixture was stirred under reflux for 18 hours to complete the reaction. Then, the temperature was lowered. The obtained solid was filtered, and the residue was purified by column chromatography using MC and hexane, thereby obtaining 0.56 g (37%) of Compound 123. The obtained product was confirmed by Mass and HPLC analysis.




**[0360]** HRMS (MALDI) calcd for  $C_{51}H_{42}N_4OPt$ :  $m/z$  921.3006, Found: 921.3001


#### Synthesis Example 2: Compound 128

**[0361]** Synthesis of Ligand 128L

**[0357]** Compound A (1.4 g, 2.9 mmol), Intermediate P1 (1.3 g, 2.9 mmol),  $Pd(PPh_3)_4$  (0.24 g, 0.2 mmol), and  $K_2CO_3$  (1.2 g, 8.7 mmol) were mixed with 60 mL of THF and 20 mL of distilled water, and the mixture was stirred under reflux for 12 hours. After the temperature was lowered down to room temperature, the organic layer was extracted therefrom with MC. The combined organic extracts were dried over anhydrous magnesium sulfate ( $MgSO_4$ ) and filtered. The obtained filtrate was concentrated under reduced pressure and the residue was purified by column chromatography using MC and hexane, thereby completing the preparation of 1.2 g (56%) of Ligand 123L.

**[0358]** Synthesis of Compound 123







Ligand 128L

**[0362]** Compound A (2.1 g, 4.3 mmol), Compound B (2.0 g, 4.3 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.35 g, 0.3 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.8 g, 13.0 mmol) were mixed with 60 mL of THF and 20 mL of distilled water, and the mixture was stirred under reflux for 12 hours. After the temperature was lowered to room temperature, the organic layer was extracted therefrom with MC. The combined organic extracts were dried over anhydrous magnesium sulfate (MgSO<sub>4</sub>) and filtered. The obtained filtrate was subjected to reduced pressure and the residue was purified by column chromatography using MC and hexane, thereby completing the preparation of 1.5 g (48%) of Ligand 128L.

**[0363]** Synthesis of Compound 128



Ligand 128L



Compound 128

**[0364]** Ligand 128L (1.5 g, 2.1 mmol) and K<sub>2</sub>PtCl<sub>4</sub> (1.1 g, 2.3 mmol) were mixed with 60 mL of acetic acid, and the

mixture was stirred under reflux for 18 hours to complete a reaction. Then, the temperature was lowered. The obtained solid was filtered, and the residue was purified by column chromatography using MC and hexane, thereby obtaining 1.0 g (53%) of Compound 128. The obtained product was confirmed by Mass and HPLC analysis.


**[0365]** HRMS (MALDI) calcd for C<sub>51</sub>H<sub>42</sub>N<sub>4</sub>O<sub>2</sub>: m/z 921.3006, Found: 921.2997 Example 1

**[0366]** A glass substrate with an ITO electrode thereon was cut to a size of 50 mm×50 mm×0.5 mm (mm=millimeter), sonicated in acetone, iso-propyl alcohol and pure water, each for 15 minutes, and washed by exposure to UV ozone for 30 minutes, thereby preparing an ITO electrode on the glass substrate.





**[0367]** Then, m-MTDATA was deposited on the ITO electrode on the glass substrate at a deposition rate of 1 Angstrom per second (Å/sec) to form a hole injection layer having a thickness of 600 Angstroms (Å), and α-NPD (NPB) was deposited on the hole injection layer at a deposition rate of 1 Å/sec to form a hole transport layer having a thickness of 250 Å.

**[0368]** Compound 123 (dopant) and CBP (host) were co-deposited on the hole transport layer at deposition rates of 0.1 Å/sec and 1 Å/sec, respectively, to form an emission layer having a thickness of 400 Å.

**[0369]** BAQ was deposited on the emission layer at a deposition rate of 1 Å/sec to form a hole blocking layer having a thickness of 50 Å, Alq<sub>3</sub> was deposited on the hole blocking layer to form an electron transport layer having a thickness of 300 Å, LiF was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å, and Al was vacuum-deposited on the electron injection layer to form a second electrode (cathode) having a thickness of 1,200 Å, thereby completing the manufacture of an organic light-emitting device having the structure of ITO/m-MTDATA (600 Å)/α-NPD (250 Å)/CBP+Compound 123 (10%) (400 Å)/BAQ(50 Å)/Alq<sub>3</sub> (300 Å)/LiF(10 Å)/Al(1,200 Å).



m-MTDATA



#### Example 2 and Comparative Example 1

**[0370]** Organic light-emitting devices were manufactured in the same manner as in Example 1, except that in forming an emission layer, for use as a dopant, corresponding compounds shown in Table 2 were used instead of Compound 123.

#### Evaluation Example 1: Evaluation on Characteristics of Organic Light-Emitting Devices

**[0371]** The driving voltage, the luminescent quantum efficiency, the roll-off ratio, and the lifespan ( $T_{95}$ ) of each of the organic light-emitting devices manufactured according to Examples 1 and 2 and Comparative Example 1 were evaluated and the results are shown in Table 2. As evaluation


devices, a current-voltage meter (Keithley 2400) and a luminance meter (Minolta Cs-1000A) were used, and the lifetime ( $T_{95}$ ) (at 6000 nit) was a relative value of the time taken when the luminance becomes 95% of the initial luminance 100% with respect to the lifespan ( $T_{95}$ ) of Example 1. The roll-off ratio was calculated by the following equation:

$$\text{Roll off} = \{1 - (\text{efficiency at 9000 nit} / \text{maximum luminescent efficiency})\} \times 100\% \quad \text{Equation 20}$$


TABLE 2

	Dopant	Driving	Luminescent	Roll-off	Lifespan
		voltage	quantum		
		Voltage	Efficiency	ratio	(relative
		(V)	(%)	(%)	value)
					( $T_{95}$ )
Example 1	Compound 123	4.26	22.6	10%	100%
Example 2	Compound 128	4.21	25.2	13%	112%
Comparative Example 1	Compound A	4.57	18.7	11%	17%


123



128



-continued



A

[0372] From Table 2, it can be seen that the organic light-emitting devices of Examples 1 and 2 have better characteristics than the organic light-emitting device of Comparative Example 1 in terms of driving voltage, luminescent quantum efficiency, roll-off ratio, and lifespan.

[0373] The organometallic compound according to embodiments has excellent electric characteristics and thermal stability. Accordingly, an organic light-emitting device including the organometallic compound may have excellent characteristics in terms of driving voltage, efficiency, power, color purity, and lifespan. The organometallic compound has excellent phosphorescent luminescent characteristics. Accordingly, the organometallic compound can provide a diagnostic composition having high diagnostic efficiency.


[0374] It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.

[0375] While one or more embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope as defined by the following claims.

What is claimed is:

1. An organometallic compound represented by Formula 1:

Formula 1



wherein, in Formula 1,

M is beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium

(Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au),

X<sub>1</sub> is a chemical bond, O, S, N(R'), P(R'), B(R'), C(R') (R''), Si(R')(R''), or N(R')(R''), and when X<sub>1</sub> is a chemical bond, Y<sub>1</sub> is directly bonded with M,

a bond between X<sub>1</sub> and M is a covalent bond,

X<sub>2</sub> to X<sub>4</sub> are each independently N or C,

one bond selected from a bond between X<sub>2</sub> and M, a bond between X<sub>3</sub> and M, and a bond between X<sub>4</sub> and M is a covalent bond, and the remaining two bonds are coordinate bonds,

Y<sub>1</sub> and Y<sub>3</sub> to Y<sub>5</sub> are each independently C or N,

regarding a pair of X<sub>2</sub> and Y<sub>3</sub>, a pair of X<sub>2</sub> and Y<sub>4</sub>, a pair of Y<sub>4</sub> and Y<sub>5</sub>, a pair of X<sub>51</sub> and Y<sub>3</sub>, and a pair of X<sub>51</sub> and Y<sub>5</sub>, components constituting each pair are connected to each other via a chemical bond,

CY<sub>1</sub> to CY<sub>5</sub> are each independently selected from a C<sub>5</sub>-C<sub>30</sub> carbocyclic group and a C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

a cyclometalated ring formed by CY<sub>5</sub>, CY<sub>2</sub>, CY<sub>3</sub>, and M is a 6-membered ring,

X<sub>51</sub> is selected from O, S, N-[(L<sub>7</sub>)<sub>b7</sub>-(R<sub>7</sub>)<sub>c7</sub>], C(R<sub>7</sub>)(R<sub>8</sub>), Si(R<sub>7</sub>)(R<sub>8</sub>), Ge(R<sub>7</sub>)(R<sub>8</sub>), C(=O), N, C(R<sub>7</sub>), Si(R<sub>7</sub>), and Ge(R<sub>7</sub>),

R<sub>7</sub> and R<sub>8</sub> are optionally bonded to each other via a first linking group to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

L<sub>1</sub> to L<sub>4</sub> and L<sub>7</sub> are each independently selected from a single bond, a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, and a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

b1 to b4 and b7 are each independently an integer from 1 to 5,

R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R', and R'' are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF<sub>5</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> arylthio group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), and —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>),

c1 to c4 and c7 are each independently an integer from 1 to 5,

Z<sub>1</sub> to Z<sub>4</sub> are each independently a cyano group (CN)-containing group,

a1 to a4 and n1, n2, n3, and n4 are each independently an integer from 0 to 20,

two of a plurality of neighboring groups R<sub>1</sub> are optionally linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

two of a plurality of neighboring groups R<sub>2</sub> are optionally linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

two of a plurality of neighboring groups R<sub>3</sub> are optionally linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

two of a plurality of neighboring groups R<sub>4</sub> are optionally linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

two or more neighboring substituents selected from groups R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, and R<sub>8</sub> are optionally linked to form a substituted or unsubstituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a substituted or unsubstituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

i) when X<sub>51</sub> is O, S, C(=O), or N, the sum of n1, n2, n3, and n4 is 1 or more, ii) when X<sub>51</sub> is N[(L<sub>7</sub>)<sub>b7</sub>-(R<sub>7</sub>)<sub>c7</sub>], C(R<sub>7</sub>), Si(R<sub>7</sub>), or Ge(R<sub>7</sub>), R<sub>7</sub> is a cyano group-containing group or the sum of n1, n2, n3, and n4 is 1 or more, iii) when X<sub>51</sub> is C(R<sub>7</sub>)(R<sub>8</sub>), Si(R<sub>7</sub>)(R<sub>8</sub>), or Ge(R<sub>7</sub>)(R<sub>8</sub>), at least one selected from R<sub>7</sub> and R<sub>8</sub> is a cyano group-containing group or the sum of n1, n2, n3, and n4 is 1 or more,

at least one of substituents of the substituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, substituted C<sub>1</sub>-C<sub>30</sub> heterocyclic group, substituted C<sub>1</sub>-C<sub>60</sub> alkyl group, substituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, substituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, substituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, substituted C<sub>6</sub>-C<sub>60</sub> aryl group, substituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, substituted C<sub>6</sub>-C<sub>60</sub> arylthio group, substituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, substituted monovalent non-aromatic condensed polycyclic group, and substituted monovalent non-aromatic condensed heteropolycyclic group is selected from:

deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, and a C<sub>1</sub>-C<sub>60</sub> alkoxy group;

a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, and a C<sub>1</sub>-C<sub>60</sub> alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalk-

enyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>11</sub>)(Q<sub>12</sub>), —Si(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —B(Q<sub>16</sub>)(Q<sub>17</sub>), and —P(=O)(Q<sub>18</sub>)(Q<sub>19</sub>);

a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>21</sub>)(Q<sub>22</sub>), —Si(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —B(Q<sub>26</sub>)(Q<sub>27</sub>), and —P(=O)(Q<sub>28</sub>)(Q<sub>29</sub>); and

—N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>), and —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>),

wherein Q<sub>1</sub> to Q<sub>9</sub>, Q<sub>11</sub> to Q<sub>19</sub>, Q<sub>21</sub> to Q<sub>29</sub>, and Q<sub>31</sub> to Q<sub>39</sub> are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>1</sub>-C<sub>60</sub> alkyl group substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, and a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryl group substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, and a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

2. The organometallic compound of claim 1, wherein

i) X<sub>2</sub> and X<sub>4</sub> are each N, X<sub>3</sub> is C, a bond between X<sub>2</sub> and M and a bond between X<sub>4</sub> and M are each a coordinate bond, and a bond between X<sub>3</sub> and M is a covalent bond,

- ii)  $X_3$  and  $X_4$  are each N,  $X_2$  is N, a bond between  $X_3$  and M and a bond between  $X_4$  and M are each a coordinate bond, and a bond between  $X_2$  and M is a covalent bond,
- iii)  $X_2$  and  $X_3$  are each N,  $X_4$  is N, a bond between  $X_2$  and M is a covalent bond, and a bond between  $X_3$  and M and a bond between  $X_4$  and M are each a coordinate bond, or
- iv)  $X_2$  and  $X_3$  are each N,  $X_4$  is C, a bond between  $X_2$  and M and a bond between  $X_3$  and M are each a coordinate bond, and a bond between  $X_4$  and M is a covalent bond.

**3.** The organometallic compound of claim 1, wherein

CY1 to CY4 are each independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline.

**4.** The organometallic compound of claim 1, wherein

- i)  $Y_3$  to  $Y_5$  are each C, a bond between  $X_{51}$  and  $Y_3$  and a bond between  $X_{51}$  and  $Y_5$  are each a single bond, and  $X_{51}$  is O, S, N-[( $L_7$ )<sub>67</sub>-( $R_7$ )<sub>67</sub>], C( $R_7$ )( $R_8$ ), Si( $R_7$ )( $R_8$ ), Ge( $R_7$ )( $R_8$ ), or C(=O),
- ii)  $Y_3$  and  $Y_4$  are each C,  $Y_5$  is N, a bond between  $X_{51}$  and  $Y_3$  is a double bond, a bond between  $X_{51}$  and  $Y_5$  is a single bond, and  $X_{51}$  is N, C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ),
- iii)  $Y_3$  and  $Y_5$  are each C,  $Y_4$  is N, a bond between  $X_{51}$  and  $Y_3$  is a single bond, a bond between  $X_{51}$  and  $Y_5$  is a double bond, and  $X_{51}$  is N, C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ),
- iv)  $Y_3$  is N,  $Y_4$  and  $Y_5$  are each C, a bond between  $X_{51}$  and  $Y_3$  is a single bond, a bond between  $X_{51}$  and  $Y_5$  is a double bond, and  $X_{51}$  is N, C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ), or
- v)  $Y_3$  to  $Y_5$  are each C, a bond between  $X_{51}$  and  $Y_3$  is a double bond, a bond between  $X_{51}$  and  $Y_5$  is a single bond, and  $X_{51}$  is N, C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ).

**5.** The organometallic compound of claim 1, wherein

$R_1$  to  $R_4$ ,  $R_7$ ,  $R_8$ ,  $R'$ , and  $R''$  are each independently selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF<sub>5</sub>, C<sub>1</sub>-C<sub>20</sub> alkyl group, and a C<sub>1</sub>-C<sub>20</sub> alkoxy group;

a C<sub>1</sub>-C<sub>20</sub> alkyl group and a C<sub>1</sub>-C<sub>20</sub> alkoxy group, each substituted with at least one selected from deuterium,

—F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>10</sub> alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

- a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;
- a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from; and

deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>20</sub> alkyl group, a C<sub>1</sub>-C<sub>20</sub> alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), and

—N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>) and —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>),

wherein Q<sub>1</sub> to Q<sub>9</sub> and Q<sub>33</sub> to Q<sub>35</sub> are each independently selected from:

—CH<sub>3</sub>, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CH<sub>2</sub>CH<sub>3</sub>, —CH<sub>2</sub>CD<sub>3</sub>, —CH<sub>2</sub>CD<sub>2</sub>H, —CH<sub>2</sub>CDH<sub>2</sub>, —CHDCCH<sub>3</sub>, —CHDCD<sub>2</sub>H, —CHDCDH<sub>2</sub>, —CHDCD<sub>3</sub>, —CD<sub>2</sub>CD<sub>3</sub>, —CD<sub>2</sub>CD<sub>2</sub>H, and —CD<sub>2</sub>CDH<sub>2</sub>;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and


an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C<sub>1</sub>-C<sub>10</sub> alkyl group, and a phenyl group.

6. The organometallic compound of claim 1, wherein

R<sub>1</sub> to R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R', and R'' are each independently selected from hydrogen, deuterium, —F, a cyano group, a nitro group, —SF<sub>5</sub>, —CH<sub>3</sub>, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, —C(CD<sub>3</sub>)<sub>3</sub>, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-140, —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), and —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>):



Formula 9-1




Formula 9-2




Formula 9-3




Formula 9-4




Formula 9-5




Formula 9-6




Formula 9-7




Formula 9-8




Formula 9-9




Formula 9-10




Formula 9-11




Formula 9-12




Formula 9-13




Formula 9-14



Formula 9-15















Formula 9-16



Formula 9-17

-continued



Formula 9-18

Formula 9-19

Formula 10-1

Formula 10-2

Formula 10-3

Formula 10-4

Formula 10-5

Formula 10-6












Formula 10-7

Formula 10-8

Formula 10-9

Formula 10-10

-continued



Formula 10-11

Formula 10-12

Formula 10-13

Formula 10-14

Formula 10-15

Formula 10-16

Formula 10-17












Formula 10-18

Formula 10-19

Formula 10-20

Formula 10-21

-continued



Formula 10-22

Formula 10-23

Formula 10-24

Formula 10-25

Formula 10-26

Formula 10-27

Formula 10-28











Formula 10-29

Formula 10-30

Formula 10-31

Formula 10-32

-continued



Formula 10-33

Formula 10-34

Formula 10-35

Formula 10-36

Formula 10-37

Formula 10-38











Formula 10-39

Formula 10-40


Formula 10-41

Formula 10-42


-continued



Formula 10-43




Formula 10-44




Formula 10-45

Formula 10-46




Formula 10-47


Formula 10-48




Formula 10-49




Formula 10-50



Formula 10-51



Formula 10-52



-continued

Formula 10-53

Formula 10-54

Formula 10-55

Formula 10-56











Formula 10-57

Formula 10-58


Formula 10-59

Formula 10-60


-continued




Formula 10-61




Formula 10-62




Formula 10-63




Formula 10-64



Formula 10-65



Formula 10-66




Formula 10-67

Formula 10-68

Formula 10-69

Formula 10-70



-continued

Formula 10-71

Formula 10-72

Formula 10-73








Formula 10-74

Formula 10-75



Formula 10-76

Formula 10-77




-continued






Formula 10-78




Formula 10-79




Formula 10-80




Formula 10-81





Formula 10-82



Formula 10-83



Formula 10-84



-continued

Formula 10-85

Formula 10-86

Formula 10-87

Formula 10-88

Formula 10-89

Formula 10-90

Formula 10-91

Formula 10-92

Formula 10-93












Formula 10-94

Formula 10-95

Formula 10-96


Formula 10-97

-continued




-continued

Formula 10-98




Formula 10-99




Formula 10-100

Formula 10-101




Formula 10-102

Formula 10-103




Formula 10-104




Formula 10-105


Formula 10-106



Formula 10-107



Formula 10-108



Formula 10-109

Formula 10-110

Formula 10-111

Formula 10-112








Formula 10-113

Formula 10-114

Formula 10-115


Formula 10-116

-continued




-continued


Formula 10-117




Formula 10-118




Formula 10-119




Formula 10-120





Formula 10-121



Formula 10-122



Formula 10-123



Formula 10-124

Formula 10-125

Formula 10-126

Formula 10-127


Formula 10-128

Formula 10-129


Formula 10-130

Formula 10-131


-continued




Formula 10-132




Formula 10-133




Formula 10-134




Formula 10-135



Formula 10-136




Formula 10-137




Formula 10-138

-continued



Formula 10-139



Formula 10-140

wherein, in Formulae 9-1 to 9-19 and 10-1 to 10-140,

\* indicates a binding site to a neighboring atom,

“Ph” indicates a phenyl group, and

“TMS” indicates a trimethylsilyl group.

7. The organometallic compound of claim 1, wherein

the cyano group-containing group is a cyano group or a first group substituted with at least one cyano group,

wherein the first group is selected from a substituted or unsubstituted  $C_1$ - $C_{60}$  alkyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkenyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkynyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  alkoxy group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkyl group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkenyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkenyl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryloxy group, a substituted or unsubstituted  $C_6$ - $C_{60}$  arylthio group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.

8. The organometallic compound of claim 1, wherein the sum of  $n_1$ ,  $n_2$ ,  $n_3$ , and  $n_4$  is 1, 2, 3, or 4.

9. The organometallic compound of claim 1, wherein

i)  $n_1=n_2=n_3=0$ , and  $n_4=1$ ,

ii)  $n_1=n_2=n_4=0$ , and  $n_3=1$ ,

iii)  $n_1=n_3=n_4=0$ , and  $n_2=1$ ,

iv)  $n_2=n_3=n_4=0$ , and  $n_1=1$ ,


v)  $n_1=n_2=0$ , and  $n_3=n_4=1$ ,

vi)  $n_2=n_3=0$ , and  $n_1=n_4=1$ ,

vii)  $n_2=n_4=0$ , and  $n_1=n_3=1$ , or


viii)  $n_1=n_3=0$ , and  $n_2=n_4=1$ .

10. The organometallic compound of claim 1, wherein  
i)  $X_1$  is a chemical bond, and a moiety represented by




is a group represented by Formula CY1-B, or


ii)  $X_1$  is O, S, N(R'), P(R'), B(R'), C(R')(R''), Si(R')(R''), or N(R')(R''), and a moiety represented by



is a group represented by Formula CY1-A:




Formula CY1-A




Formula CY1-B

wherein, in Formulae CY1-A and CY1-B,  $Y_1$ ,  $CY_1$ ,  $L_1$ ,  $b_1$ ,  $R_1$ ,  $c_1$ ,  $a_1$ ,  $Z_1$ , and  $n_1$  are the same as described in connection with claim 1,  $Y_2$  and  $Y_6$  are each independently N or C, and a bond between  $Y_1$  and  $Y_2$ , a bond between  $Y_1$  and  $Y_6$ , and a bond between  $Y_6$  and  $Y_2$  are each a chemical bond.


11. The organometallic compound of claim 1, wherein  
a moiety represented by




in Formula 1 is a group represented by one of Formulae CY1-1 to CY1-40:




Formula CY1-1




Formula CY1-2




Formula CY1-3




Formula CY1-4




Formula CY1-5



Formula CY1-6




Formula CY1-7




Formula CY1-8


-continued




Formula CY1-9




Formula CY1-10




Formula CY1-11



Formula CY1-12




Formula CY1-13




Formula CY1-14


-continued




Formula CY1-15




Formula CY1-16




Formula CY1-17




Formula CY1-18



Formula CY1-19




Formula CY1-20




Formula CY1-21


-continued




Formula CY1-22




Formula CY1-23




Formula CY1-24



Formula CY1-25




Formula CY1-26




Formula CY1-27


-continued




Formula CY1-28




Formula CY1-29




Formula CY1-30



Formula CY1-31




Formula CY1-32




Formula CY1-33


-continued




Formula CY1-34




Formula CY1-35




Formula CY1-36




Formula CY1-37



Formula CY1-38



Formula CY1-39



Formula CY1-40

wherein, in Formulae CY1-1 to CY1-40,

$Y_1$ ,  $R_1$ ,  $Z$ , and  $n_1$  are the same as described in connection with claim 1,  $n_1$  is 0, 1, or 2,

$X_{19}$  is  $C(R_{19a})(R_{19b})$ ,  $N[(L_{19})_{b19}-(R_{19})_{c19}]$ , O, S, or  $Si(R_{19a})(R_{19b})$ ,

$L_{19}$  is the same as described in connection with  $L_1$  in claim 1,

$b_{19}$  and  $c_{19}$  are the same as described in connection with  $b_1$  and  $c_1$  in claim 1, respectively,

$R_{11}$  to  $R_{19}$ ,  $R_{19a}$ , and  $R_{19b}$  are the same as described in connection with  $R_1$  in claim 1,

$a_{12}$  is an integer from 0 to 2,

$a_{13}$  is an integer from 0 to 3,

$a_{14}$  is an integer from 0 to 4,

$a_{15}$  is an integer from 0 to 5,


$a_{16}$  is an integer from 0 to 6,

$a_{17}$  is an integer from 0 to 7,

\* indicates a binding site to M in Formula 1, and


\* indicates a binding site to  $CY_5$  in Formula 1.

12. The organometallic compound of claim 1, wherein a moiety represented by




Formula CY1-37


in Formula 1 is a group represented by one of Formulae CY2-1 to CY2-20:



Formula CY2-1




Formula CY2-2




Formula CY2-3


-continued




Formula CY2-4




Formula CY2-5




Formula CY2-6




Formula CY2-7



Formula CY2-8




Formula CY2-9




Formula CY2-10


-continued




Formula CY2-11




Formula CY2-12




Formula CY2-13




Formula CY2-14



Formula CY2-15




Formula CY2-16




Formula CY2-17


-continued



Formula CY2-18



Formula CY2-19



Formula CY2-20

wherein, in Formulae CY2-1 to CY2-20,

$R_2$ ,  $Z_2$ , and  $n_2$  are the same as described in connection with claim 1,  $n_2$  is 0, 1, or 2,

$X_{51}$  in Formulae CY2-1 to CY2-4 is O, S, N-[( $L_7$ ) $b_7$ -( $R_7$ ) $c_7$ ], C( $R_7$ )( $R_8$ ), Si( $R_7$ )( $R_8$ ), Ge( $R_7$ )( $R_8$ ), or C(=O),

$X_{51}$  in Formulae CY2-5 to CY2-20 is N, C( $R_7$ ), Si( $R_7$ ), or Ge( $R_7$ ),

$L_7$ ,  $b_7$ ,  $R_7$ , and  $c_7$  are the same as described in connection with claim 1,

$a_{22}$  is an integer from 0 to 2,


$a_{23}$  is an integer from 0 to 3,

\* indicates a binding site to  $CY_1$  in Formula 1,


\*<sup>1</sup> indicates a binding site to M in Formula 1, and

\*<sup>11</sup> indicates a binding site to  $CY_3$  in Formula 1.


13. The organometallic compound of claim 1, wherein a moiety represented by




in Formula 1 is a group represented by one of Formulae CY3-1 to CY3-12:




Formula CY3-1




Formula CY3-2




Formula CY3-3




Formula CY3-4




Formula CY3-5



Formula CY3-6




Formula CY3-7




Formula CY3-8


-continued




Formula CY3-9



Formula CY3-10



Formula CY3-11



Formula CY3-12

wherein, in Formulae CY3-1 to CY3-12,

$X_3$ ,  $R_3$ ,  $Z_3$ , and  $n_3$  are the same as described in connection with claim 1,  $n_3$  is 0, 1 or 2,

$X_{39}$  is  $C(R_{39a})(R_{39b})$ ,  $N[(L_{39})_{b39}-(R_{39})_{c39}]$ , O, S, or  $Si(R_{39a})(R_{39b})$ ,

$L_{39}$  is the same as described in connection with  $L_3$  in claim 1,

$b_{39}$  and  $c_{39}$  are the same as described in connection with  $b_3$  and  $c_3$  recited in claim 1, respectively,

$R_{39a}$  and  $R_{39b}$  are the same as described in connection with  $R_3$  in claim 1,

$a_{32}$  is an integer from 0 to 2,

$a_{33}$  is an integer from 0 to 3,

$a_{34}$  is an integer from 0 to 4,


$a_{35}$  is an integer from 0 to 5,

\* indicates a binding site to  $CY_4$  in Formula 1,


\*' indicates a binding site to M in Formula 1, and

\*\* indicates a binding site to  $CY_2$  in Formula 1.


14. The organometallic compound of claim 1, wherein a moiety represented by




in Formula 1 is a group represented by one of Formulae CY4-1 to CY4-26:




Formula CY4-1




Formula CY4-2




Formula CY4-3



Formula CY4-4




Formula CY4-5




Formula CY4-6


-continued




Formula CY4-7




Formula CY4-8




Formula CY4-9



Formula CY4-10




Formula CY4-11




Formula CY4-12


-continued




Formula CY4-13




Formula CY4-14




Formula CY4-15




Formula CY4-16



Formula CY4-17




Formula CY4-18




Formula CY4-19


-continued




Formula CY4-20




Formula CY4-21




Formula CY4-22



Formula CY4-23




Formula CY4-24



Formula CY4-25

-continued



Formula CY4-26

wherein, in Formulae CY4-1 to CY4-26,

$X_4$ ,  $R_4$ ,  $Z_4$ , and  $n_4$  are the same as described in connection with claim 1,  $n_4$  is 0, 1, or 2,

$X_{49}$  is  $C(R_{49a})(R_{49b})$ ,  $N[(L_{49})_{b49}-(R_{49})_{c49}]$ , O, S, or  $Si(R_{49a})(R_{49b})$ ,

$L_{49}$  is the same as described in connection with  $L_4$  in claim 1,

$b_{49}$  and  $c_{49}$  are the same as described in connection with  $b_4$  and  $c_4$  in claim 1, respectively,

$R_{41}$  to  $R_{49}$ ,  $R_{49a}$  and  $R_{49b}$  are the same as described in connection with  $R_4$  in claim 1,

$a_{42}$  is an integer from 0 to 2,

$a_{43}$  is an integer from 0 to 3,

$a_{44}$  is an integer from 0 to 4,


$a_{45}$  is an integer from 0 to 5,

$a_{46}$  is an integer from 0 to 6,


\* indicates a binding site to  $CY_3$  in Formula 1, and

\*' indicates a binding site to M in Formula 1.

15. The organometallic compound of claim 1, wherein the organometallic compound is one of Compounds 1 to 190 below:








1




2

-continued




-continued

3




8

4




9

5




10

6




11

7




12


-continued




13




14



15




16




17


-continued




18




19



20




21




22

-continued




23


-continued




28




24




29




25




30



26




31




27


-continued




32



33




34




35


-continued




36




37



38




39




40

-continued




41


-continued




45




42




46




43




47



44








48








49


-continued



-continued




-continued




60


-continued




64




61




65




62



66




63




67

-continued




68


-continued




72




69




73




70



74




71




75

-continued




76


-continued




80




77




81




78



82




79




83

-continued




84


-continued




88




85




89




86



90




87



91


-continued

92




-continued

95




96

93






97


94




98




-continued




-continued




100




104




101




105




102




106




-continued




-continued




108




112




109




113



110




114




116

-continued




115

119




116






117

120




118







121



-continued




-continued




-continued

129




-continued


132




130




133




131




134




-continued




-continued




136




140




137




141



138




142




-continued


143




144



145




146




-continued


147



148




149




-continued

150




-continued


154




151




155




152




156




153





-continued



-continued





158



161


162

159










163


-continued



-continued




-continued




172

-continued




176


173




177



174




175




178


-continued




-continued




180




183




181




184



-continued





-continued





188

186



189

187



190

16. An organic light-emitting device comprising:  
 a first electrode;  
 a second electrode; and  
 an organic layer disposed between the first electrode and  
 the second electrode,  
 wherein the organic layer comprising an emission layer,  
 and

wherein the organic layer comprises at least one organometallic compound of claim 1.

**17.** The organic light-emitting device of claim 16, wherein the first electrode is an anode,

the second electrode is a cathode, and

the organic layer further comprises a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode,

wherein the hole transport region comprises a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and

wherein the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

**18.** The organic light-emitting device of claim 16, wherein the emission layer comprises the at least one organometallic compound.

**19.** The organic light-emitting device of claim 18, wherein the emission layer further comprises a host, and wherein an amount of the host is greater than an amount of the at least one organometallic compound.

**20.** A diagnostic composition comprising at least one organometallic compound of claim 1.

\* \* \* \* \*

专利名称(译)	有机化合物，包括相同的有机发光装置和包括有机化合物在内的诊断成分		
公开(公告)号	<a href="#">US20190036045A1</a>	公开(公告)日	2019-01-31
申请号	US16/043323	申请日	2018-07-24
[标]申请(专利权)人(译)	三星电子株式会社		
申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
当前申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
[标]发明人	HWANG KYUYOUNG KWAK SEUNGYEON KIM SOYEON LEE SUNYOUNG LEE JUNGIN CHOI HYEONHO CHOI WHAIL KWAK YOONHYUN CHOI BYOUNGKI		
发明人	HWANG, KYUYOUNG KWAK, SEUNGYEON KIM, SOYEON LEE, SUNYOUNG LEE, JUNGIN CHOI, HYEONHO CHOI, WHAIL KWAK, YOONHYUN CHOI, BYOUNGKI		
IPC分类号	H01L51/00 C07F15/00 C09K11/06		
CPC分类号	H01L51/5088 H01L51/5056 C09K2211/1044 H01L51/5072 H01L51/5092 H01L51/5004 H01L51/5016 C09K2211/185 H01L51/5096 H01L51/0087 C07F15/0086 C09K11/06 H01L2251/552 H01L51/0081		
优先权	1020170094963 2017-07-26 KR		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

由式1表示的有机金属化合物：其中，在公式1中，组和变量与规范中描述的相同。

